0001193125-26-350448.txt : 20260814 0001193125-26-350448.hdr.sgml : 20260814 20260814080038 ACCESSION NUMBER: 0001193125-26-350448 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20260630 FILED AS OF DATE: 20260814 DATE AS OF CHANGE: 20260814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PMV Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001699382 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 463218129 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39539 FILM NUMBER: 261276230 BUSINESS ADDRESS: STREET 1: 400 ALEXANDER PARK DRIVE STREET 2: SUITE 301 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: (609) 642-6670 MAIL ADDRESS: STREET 1: 400 ALEXANDER PARK DRIVE STREET 2: SUITE 301 CITY: PRINCETON STATE: NJ ZIP: 08540 10-Q 1 pmvp-20260630.htm 10-Q 10-Q
0001699382false--12-31Q23 year2015 2016 2017 2018 2019 2020 2021 2022 2023http://fasb.org/srt/2026#ChiefExecutiveOfficerMember0001699382us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001699382pmvp:OptionExchangeMember2024-08-132024-08-130001699382us-gaap:ComputerEquipmentMember2026-06-300001699382pmvp:BoardOfDirectorsMember2026-06-300001699382pmvp:AtTheMarketEquityOfferingProgramMember2026-06-300001699382us-gaap:FairValueInputsLevel1Member2025-12-310001699382us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2026-06-300001699382pmvp:OptionsToPurchaseCommonStockMember2026-01-012026-06-3000016993822025-12-310001699382us-gaap:OperatingSegmentsMemberus-gaap:GeneralAndAdministrativeExpense2025-01-012025-06-300001699382us-gaap:CommonStockMember2025-06-300001699382us-gaap:RestrictedStockUnitsRSUMember2026-04-012026-06-300001699382us-gaap:CommonStockMember2026-06-300001699382us-gaap:ResearchAndDevelopmentExpense2026-04-012026-06-300001699382us-gaap:MoneyMarketFundsMember2026-06-300001699382us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-3100016993822025-03-310001699382pmvp:BoardOfDirectorsMember2025-01-012025-06-300001699382us-gaap:RetainedEarningsMember2025-06-300001699382us-gaap:MachineryAndEquipmentMember2025-12-310001699382us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001699382pmvp:BoardOfDirectorsMember2026-04-012026-06-300001699382pmvp:AtTheMarketEquityOfferingProgramMember2026-01-012026-06-300001699382us-gaap:FairValueInputsLevel2Member2025-12-310001699382us-gaap:RetainedEarningsMember2026-04-012026-06-300001699382us-gaap:AdditionalPaidInCapitalMember2025-06-300001699382us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2026-06-300001699382us-gaap:OperatingSegmentsMemberus-gaap:ResearchAndDevelopmentExpense2026-01-012026-06-300001699382us-gaap:FurnitureAndFixturesMember2025-12-310001699382pmvp:ExpectedSharesToBePurchasedUnderTwoThousandTwentyEsppMember2026-01-012026-06-300001699382pmvp:BmrOneResearchWayLlcMemberpmvp:LeaseTerminationAgreementMemberpmvp:PrincetonNewJerseyMember2024-08-012024-08-310001699382us-gaap:ResearchAndDevelopmentExpense2025-04-012025-06-3000016993822026-01-012026-03-3100016993822025-01-012025-12-310001699382us-gaap:RetainedEarningsMember2025-12-310001699382pmvp:SubleaseAgreementMemberpmvp:HopewellNewJerseyMember2024-09-012024-09-300001699382us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001699382srt:MaximumMember2025-01-012025-06-300001699382us-gaap:RetainedEarningsMember2025-04-012025-06-300001699382us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001699382us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001699382pmvp:PrincetonNewJerseyMember2021-01-310001699382pmvp:HopewellNewJerseyMember2026-03-310001699382pmvp:BmrOneResearchWayLlcMemberpmvp:LeaseTerminationAgreementMemberpmvp:PrincetonNewJerseyMemberus-gaap:GeneralAndAdministrativeExpense2024-01-012024-12-310001699382pmvp:PrincetonNewJerseyMember2021-01-012021-01-310001699382us-gaap:RetainedEarningsMember2024-12-3100016993822026-04-012026-06-300001699382us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2025-12-310001699382pmvp:AtTheMarketEquityOfferingProgramMember2026-04-012026-06-300001699382pmvp:TwoThousandTwentyEquityIncentivePlanMember2020-09-240001699382us-gaap:EmployeeStockOptionMember2026-04-012026-06-3000016993822025-01-012025-03-310001699382pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember2026-01-012026-06-300001699382us-gaap:CommonStockMember2025-03-310001699382us-gaap:CorporateDebtSecuritiesMember2026-06-300001699382us-gaap:GeneralAndAdministrativeExpense2026-04-012026-06-300001699382us-gaap:EmployeeStockOptionMember2026-01-012026-06-300001699382us-gaap:CommonStockMember2026-03-310001699382pmvp:TwoThousandTwentyEquityIncentivePlanMember2025-01-010001699382us-gaap:CommonStockMember2025-12-310001699382pmvp:SubleaseAgreementMemberpmvp:HopewellNewJerseyMember2024-09-300001699382pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember2020-09-240001699382us-gaap:AdditionalPaidInCapitalMember2026-06-300001699382pmvp:SubleaseAgreementMemberpmvp:PrincetonNewJerseyMember2024-08-012024-08-310001699382us-gaap:ResearchAndDevelopmentExpense2026-01-012026-06-300001699382us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-06-300001699382pmvp:OptionsToPurchaseCommonStockMember2025-01-012025-06-300001699382us-gaap:AdditionalPaidInCapitalMember2025-03-3100016993822026-03-310001699382us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001699382srt:MaximumMember2026-01-012026-06-300001699382pmvp:BoardOfDirectorsMember2026-01-012026-06-300001699382pmvp:HopewellNewJerseyMember2026-01-012026-03-310001699382srt:MinimumMember2026-01-012026-06-300001699382us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300001699382us-gaap:EmployeeStockOptionMember2025-04-012025-06-300001699382us-gaap:RestrictedStockUnitsRSUMember2025-04-012025-06-300001699382us-gaap:ResearchAndDevelopmentExpense2025-01-012025-06-300001699382us-gaap:GeneralAndAdministrativeExpense2025-01-012025-06-300001699382pmvp:MoneyMarketFundsAndGovernmentSecuritiesMember2025-12-310001699382us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-300001699382srt:MinimumMember2025-01-012025-06-300001699382pmvp:TwoThousandTwentyEquityIncentivePlanMember2026-06-300001699382us-gaap:GeneralAndAdministrativeExpense2026-01-012026-06-300001699382us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001699382pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember2026-06-300001699382us-gaap:RestrictedStockUnitsRSUMember2024-01-182024-01-180001699382us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-012026-06-300001699382us-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-12-310001699382pmvp:EmployeeStockPurchasePlanMember2025-01-012025-06-300001699382us-gaap:AdditionalPaidInCapitalMember2025-12-310001699382us-gaap:CommonStockMember2025-01-012025-03-310001699382us-gaap:LeaseholdsAndLeaseholdImprovementsMember2025-12-310001699382us-gaap:RetainedEarningsMember2026-03-310001699382pmvp:OptionExchangeMemberpmvp:TwoThousandTwentyEquityIncentivePlanMember2024-08-130001699382pmvp:EmployeeStockPurchasePlanMember2026-04-012026-06-300001699382pmvp:SubleaseAgreementMemberpmvp:PrincetonNewJerseyMember2024-08-310001699382pmvp:EmployeeStockPurchasePlanMember2025-04-012025-06-300001699382us-gaap:MoneyMarketFundsMember2026-06-300001699382us-gaap:FairValueInputsLevel1Member2026-06-300001699382us-gaap:AccountingStandardsUpdate202309Member2025-12-310001699382us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-06-300001699382us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2026-06-300001699382us-gaap:LeaseholdsAndLeaseholdImprovementsMember2026-06-300001699382us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-06-300001699382us-gaap:AdditionalPaidInCapitalMember2024-12-310001699382pmvp:OptionExchangeMember2024-07-160001699382us-gaap:RetainedEarningsMember2026-06-300001699382us-gaap:USGovernmentAgenciesDebtSecuritiesMember2026-06-300001699382pmvp:BoardOfDirectorsMember2025-04-012025-06-300001699382us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-300001699382pmvp:EmployeeStockPurchasePlanMember2025-01-012025-06-3000016993822026-01-012026-06-300001699382pmvp:HopewellNewJerseyMemberpmvp:SubleaseAgreementMember2025-01-012025-06-300001699382us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001699382pmvp:ExpectedSharesToBePurchasedUnderTwoThousandTwentyEsppMember2025-01-012025-06-300001699382us-gaap:CommonStockMember2025-04-012025-06-300001699382us-gaap:RestrictedStockUnitsRSUMember2026-06-300001699382pmvp:OptionExchangeMembersrt:MaximumMember2024-08-132024-08-130001699382us-gaap:MoneyMarketFundsMember2025-12-310001699382us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-06-300001699382us-gaap:ComputerEquipmentMember2025-12-310001699382us-gaap:FairValueInputsLevel2Member2026-06-300001699382us-gaap:OperatingSegmentsMemberus-gaap:GeneralAndAdministrativeExpense2026-01-012026-06-300001699382pmvp:EmployeeStockPurchasePlanMember2026-01-012026-06-300001699382us-gaap:GeneralAndAdministrativeExpense2025-04-012025-06-300001699382pmvp:OptionExchangeMember2024-08-1300016993822026-06-300001699382us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001699382srt:MinimumMemberpmvp:OptionExchangeMember2024-08-132024-08-130001699382us-gaap:CommonStockMember2026-04-012026-06-300001699382us-gaap:RetainedEarningsMember2025-03-310001699382us-gaap:RetainedEarningsMember2025-01-012025-03-310001699382pmvp:HopewellNewJerseyMemberpmvp:SubleaseAgreementMember2026-01-012026-06-300001699382us-gaap:EmployeeStockOptionMember2025-01-012025-06-300001699382pmvp:BmrOneResearchWayLlcMemberpmvp:LeaseTerminationAgreementMemberpmvp:PrincetonNewJerseyMember2024-08-310001699382us-gaap:MachineryAndEquipmentMember2026-06-300001699382us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2025-12-3100016993822025-01-012025-06-300001699382us-gaap:CorporateDebtSecuritiesMember2025-12-310001699382us-gaap:OperatingSegmentsMember2025-01-012025-06-300001699382us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001699382us-gaap:OperatingSegmentsMemberus-gaap:ResearchAndDevelopmentExpense2025-01-012025-06-3000016993822025-06-300001699382us-gaap:AdditionalPaidInCapitalMember2026-03-310001699382pmvp:NetOperatingLossAndRDTaxCreditSaleMember2025-01-012025-06-300001699382us-gaap:RetainedEarningsMember2026-01-012026-03-3100016993822024-12-310001699382us-gaap:FurnitureAndFixturesMember2026-06-300001699382us-gaap:OperatingSegmentsMember2026-01-012026-06-3000016993822025-04-012025-06-300001699382pmvp:EmployeeStockPurchasePlanMember2026-01-012026-06-300001699382pmvp:AtTheMarketEquityOfferingProgramMembersrt:MaximumMember2021-10-042021-10-040001699382pmvp:NetOperatingLossAndRDTaxCreditSaleMember2026-01-012026-06-300001699382us-gaap:CommonStockMember2024-12-3100016993822026-08-14xbrli:purepmvp:Memberutr:sqftxbrli:sharespmvp:Segmentiso4217:USDxbrli:sharesiso4217:USD

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2026

OR

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39539

 

PMV PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

46-3218129

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

400 Alexander Park Drive, Suite 301

Princeton, NJ

08540

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (609) 642-6670

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.00001

 

PMVP

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

☐

Accelerated filer

☐

 

 

 

 

Non-accelerated filer

☒

Smaller reporting company

☒

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 14, 2026, the registrant had 53,458,058 shares of common stock, $0.00001 par value per share, outstanding.

 

 

 


 

Table of Contents

 

Page

PART I.

FINANCIAL INFORMATION

1

Item 1.

Condensed Consolidated Financial Statements (Unaudited)

1

Condensed Consolidated Balance Sheets (Unaudited)

1

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

2

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

3

Condensed Consolidated Statements of Cash Flows (Unaudited)

4

Notes to Unaudited Condensed Consolidated Financial Statements

5

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

16

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

24

Item 4.

Controls and Procedures

25

PART II.

OTHER INFORMATION

26

Item 1.

Legal Proceedings

26

Item 1A.

Risk Factors

26

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

26

Item 3.

Defaults Upon Senior Securities

26

Item 4.

Mine Safety Disclosures

26

Item 5.

Other Information

26

Item 6.

Exhibits

28

Signatures

29

 

i


 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, development plans, planned preclinical studies and clinical trials, future results of clinical trials, expected research and development costs, regulatory strategy and approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:

•
our financial performance;
•
the sufficiency of our existing cash, cash equivalents, and marketable securities to fund our future operating expenses and capital expenditure requirements, and our ability to continue as a going concern;
•
our need to raise additional funding before we can expect to generate any revenues from product sales;
•
our ability to obtain additional funding for our operations, when needed, including funding necessary to complete further development and commercialization of our product candidates, if approved;
•
the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
•
our anticipated use of our existing cash, cash equivalents, and marketable securities and any proceeds from the ATM Program (as defined below);
•
the implementation of our strategic plans for our business and product candidates;
•
the size of the market opportunity for our product candidates and our ability to maximize those opportunities;
•
the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials and investigational new drug applications, or IND, and other regulatory submissions;
•
the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates;
•
our estimates of the number of patients for each of our programs including patients expected to have certain p53 mutations and the number of patients that will enroll in our clinical trials;
•
the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other favorable results;
•
our plans relating to the clinical development of our product candidates, including the disease areas to be evaluated;
•
the timing, progress and focus of our clinical trials, and the reporting of data from those trials;
•
our ability to obtain and maintain regulatory approval of our product candidates;
•
our plans relating to commercializing our product candidates, if approved;
•
the expected benefits of our existing and any potential future strategic collaborations with third parties and our ability to attract collaborators with development, regulatory and commercialization expertise;
•
the success of competing therapies that are or may become available;
•
the timing or likelihood of regulatory filings and approvals, including our expectation to seek accelerated reviews or special designations, such as breakthrough therapy and orphan drug designation, for our product candidates,

ii


 

including our intention to seek accelerated approval for rezatapopt, our lead product candidate, for a platinum-resistant/refractory ovarian cancer harboring a TP53 Y220C mutation indication;
•
our plans relating to the further development and manufacturing of our product candidates, including for additional indications that we may pursue;
•
existing regulations and regulatory developments in the United States and other jurisdictions;
•
our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;
•
our plans to rely on third parties to conduct and support preclinical and clinical development;
•
our ability to retain the continued service of our key personnel and to identify, hire and then retain additional qualified personnel; and
•
the impact of geopolitical tensions, such as the Ukraine-Russia war and the conflict in the Middle East, the impact of other disruptions resulting from public health epidemics, macroeconomic events such as future changes in trade regulations, tariff structures, global supply chain challenges, elevated inflation and interest rates and monetary policy changes (including the impact of changes to U.S. federal income tax law), instability in the global banking system, or other related disruptions on our business and the execution of our clinical trials.

 

We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in the section titled “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the United States Securities and Exchange Commission, or the SEC, on March 6, 2026, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 12, 2026, as well as in this Quarterly Report on Form 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events or otherwise.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.

iii


 

PART I—FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements (Unaudited).

PMV Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share amounts)

 

 

 

June 30,
2026
(unaudited)

 

 

December 31,
2025

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

12,469

 

 

$

37,983

 

Marketable securities, current

 

 

66,962

 

 

 

74,960

 

Prepaid expenses and other current assets

 

 

1,978

 

 

 

2,284

 

Total current assets

 

 

81,409

 

 

 

115,227

 

Property and equipment, net

 

 

154

 

 

 

237

 

Right-of-use assets

 

 

209

 

 

 

801

 

Other assets

 

 

296

 

 

 

297

 

Total assets

 

$

82,068

 

 

$

116,562

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

2,020

 

 

$

3,155

 

Accrued expenses

 

 

8,331

 

 

 

7,857

 

Operating lease liabilities, current

 

 

217

 

 

 

403

 

Total current liabilities

 

 

10,568

 

 

 

11,415

 

Operating lease liabilities, noncurrent

 

 

—

 

 

 

435

 

Total liabilities

 

 

10,568

 

 

 

11,850

 

Commitments and contingencies (see Note 6)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.00001 par value, 5,000,000 shares authorized at June 30, 2026 and December 31, 2025. No shares issued or outstanding at June 30, 2026 and December 31, 2025.

 

 

—

 

 

 

—

 

Common stock, $0.00001 par value, 1,000,000,000 shares authorized; 53,460,432 and 53,331,766 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively.

 

 

—

 

 

 

—

 

Additional paid-in capital

 

 

554,160

 

 

 

551,082

 

Accumulated deficit

 

 

(482,578

)

 

 

(446,454

)

Accumulated other comprehensive income (loss)

 

 

(82

)

 

 

84

 

Total stockholders’ equity

 

 

71,500

 

 

 

104,712

 

Total liabilities and stockholders’ equity

 

$

82,068

 

 

$

116,562

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

1


 

PMV Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited)

(in thousands, except share and per share amounts)

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

14,676

 

 

$

18,400

 

 

$

30,006

 

 

$

35,841

 

General and administrative

 

 

4,205

 

 

 

4,479

 

 

 

7,894

 

 

 

8,600

 

Total operating expenses

 

 

18,881

 

 

 

22,879

 

 

 

37,900

 

 

 

44,441

 

Loss from operations

 

 

(18,881

)

 

 

(22,879

)

 

 

(37,900

)

 

 

(44,441

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest income, net

 

 

788

 

 

 

1,690

 

 

 

1,768

 

 

 

3,625

 

Other income (expense), net

 

 

10

 

 

 

(16

)

 

 

11

 

 

 

(21

)

Total other income

 

 

798

 

 

 

1,674

 

 

 

1,779

 

 

 

3,604

 

Loss before (benefit) for income taxes

 

 

(18,083

)

 

 

(21,205

)

 

 

(36,121

)

 

 

(40,837

)

Provision (benefit) for income taxes

 

 

3

 

 

 

5

 

 

 

3

 

 

 

(2,191

)

Net loss

 

 

(18,086

)

 

 

(21,210

)

 

 

(36,124

)

 

 

(38,646

)

Unrealized (loss) on available for sale investments, net of tax

 

 

(67

)

 

 

(61

)

 

 

(168

)

 

 

(123

)

Foreign currency translation gain (loss)

 

 

—

 

 

 

(2

)

 

 

2

 

 

 

6

 

Total other comprehensive loss

 

 

(67

)

 

 

(63

)

 

 

(166

)

 

 

(117

)

Total comprehensive loss

 

$

(18,153

)

 

$

(21,273

)

 

$

(36,290

)

 

$

(38,763

)

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share -- basic and diluted

 

$

(0.34

)

 

$

(0.41

)

 

$

(0.68

)

 

$

(0.74

)

Weighted-average common shares outstanding

 

 

53,386,909

 

 

 

52,010,827

 

 

 

53,359,490

 

 

 

51,981,607

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

2


 

PMV Pharmaceuticals, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(unaudited)

(in thousands, except share amounts)

 

 

 

 

Common Stock

 

 

Additional
Paid-in

 

 

Accumulated
Other
Comprehensive

 

 

Accumulated

 

 

Total
Stockholders'

 

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

(Loss) Income

 

 

Deficit

 

 

Equity

 

Balance at December 31, 2024

 

 

 

51,935,134

 

 

$

—

 

 

$

544,653

 

 

$

139

 

 

$

(368,712

)

 

$

176,080

 

Exercise of stock options

 

 

 

19,001

 

 

 

—

 

 

 

10

 

 

 

—

 

 

 

—

 

 

 

10

 

Stock-based compensation expense

 

 

 

—

 

 

 

—

 

 

 

1,508

 

 

 

—

 

 

 

—

 

 

 

1,508

 

Net loss

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(17,436

)

 

 

(17,436

)

Unrealized loss on investments

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(62

)

 

 

—

 

 

 

(62

)

Foreign currency translation gain

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

7

 

 

 

—

 

 

 

7

 

Balance at March 31, 2025

 

 

 

51,954,135

 

 

$

—

 

 

$

546,171

 

 

$

84

 

 

$

(386,148

)

 

$

160,107

 

Exercise of stock options, common stock issued under the 2020 ESPP, and release of vested restricted stock units

 

 

 

1,039,103

 

 

 

—

 

 

 

103

 

 

 

—

 

 

 

—

 

 

 

103

 

Stock-based compensation expense

 

 

 

—

 

 

 

—

 

 

 

1,668

 

 

 

—

 

 

 

—

 

 

 

1,668

 

Net loss

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(21,210

)

 

 

(21,210

)

Unrealized loss on available for sale investments

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(61

)

 

 

—

 

 

 

(61

)

Foreign currency translation loss

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(2

)

 

 

—

 

 

 

(2

)

Balance at June 30, 2025

 

 

 

52,993,238

 

 

$

—

 

 

$

547,942

 

 

$

21

 

 

$

(407,358

)

 

$

140,605

 

 

 

 

 

Common Stock

 

 

Additional
Paid-in

 

 

Accumulated
Other
Comprehensive

 

 

Accumulated

 

 

Total
Stockholders'

 

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

(Loss) Income

 

 

Deficit

 

 

Equity

 

Balance at December 31, 2025

 

 

 

53,331,766

 

 

$

—

 

 

$

551,082

 

 

$

84

 

 

$

(446,454

)

 

$

104,712

 

Stock-based compensation expense

 

 

 

—

 

 

 

—

 

 

 

1,392

 

 

 

—

 

 

 

—

 

 

 

1,392

 

Net loss

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(18,038

)

 

 

(18,038

)

Unrealized loss on available for sale investments

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(101

)

 

 

—

 

 

 

(101

)

Foreign currency translation gain

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

2

 

 

 

—

 

 

 

2

 

Balance at March 31, 2026

 

 

 

53,331,766

 

 

$

—

 

 

$

552,474

 

 

$

(15

)

 

$

(464,492

)

 

$

87,967

 

Exercise of stock options, common stock issued under the 2020 ESPP, and release of vested restricted stock units

 

 

 

128,666

 

 

 

—

 

 

 

143

 

 

 

—

 

 

 

—

 

 

 

143

 

Stock-based compensation expense

 

 

 

—

 

 

 

—

 

 

 

1,543

 

 

 

—

 

 

 

—

 

 

 

1,543

 

Net loss

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(18,086

)

 

 

(18,086

)

Unrealized loss on investments

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(67

)

 

 

—

 

 

 

(67

)

Balance at June 30, 2026

 

 

 

53,460,432

 

 

$

—

 

 

$

554,160

 

 

$

(82

)

 

$

(482,578

)

 

$

71,500

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3


 

PMV Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

 

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$

(36,124

)

 

$

(38,646

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Stock-based compensation expense

 

 

2,935

 

 

 

3,176

 

Depreciation

 

 

58

 

 

 

69

 

Accretion of discounts on marketable securities

 

 

(767

)

 

 

(1,564

)

Non-cash lease income

 

 

(5

)

 

 

(4

)

Gain on termination of lease, net

 

 

(24

)

 

 

—

 

Loss on sales and disposals of fixed assets, net

 

 

25

 

 

 

38

 

Other, net

 

 

1

 

 

 

(16

)

Change in operating assets and liabilities:

 

 

 

 

 

 

Prepaid expenses and other assets

 

 

306

 

 

 

3,167

 

Operating lease right-of-use assets and liabilities

 

 

—

 

 

 

—

 

Accounts payable

 

 

(1,135

)

 

 

(3,981

)

Accrued expenses

 

 

474

 

 

 

1,193

 

Net cash used in operating activities

 

 

(34,256

)

 

 

(36,568

)

Cash flows from investing activities:

 

 

 

 

 

 

Purchases of property and equipment

 

 

—

 

 

 

(15

)

Proceeds from sale of property and equipment

 

 

—

 

 

 

30

 

Purchases of marketable securities

 

 

(37,404

)

 

 

(46,689

)

Maturities of marketable securities

 

 

46,001

 

 

 

86,374

 

Net cash provided by investing activities

 

 

8,597

 

 

 

39,700

 

Cash flows from financing activities:

 

 

 

 

 

 

Proceeds from the exercise of stock options and common stock issued under the 2020 Plan

 

 

143

 

 

 

113

 

Net cash provided by financing activities

 

 

143

 

 

 

113

 

Impact of exchange rates on cash and cash equivalents

 

 

2

 

 

 

6

 

Net (decrease) increase in cash and cash equivalents

 

 

(25,514

)

 

 

3,251

 

Cash and cash equivalents

 

 

 

 

 

 

Cash and cash equivalents - beginning of period

 

 

37,983

 

 

 

40,876

 

Cash and cash equivalents - end of period

 

$

12,469

 

 

$

44,127

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4


 

PMV Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share amounts)

1. Formation and Business of the Company

Organization and Liquidity

PMV Pharmaceuticals, Inc. (the “Company”) was incorporated in the state of Delaware in March 2013. Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities and raising capital. The Company is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The Company’s headquarters are located at 400 Alexander Park Drive, Suite 301, Princeton, New Jersey.

The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

The Company has incurred net losses and negative cash flows from operations since its inception. During the three and six months ended June 30, 2026, the Company incurred a net loss of $18,086 and $36,124, respectively. For the six months ended June 30, 2026, the Company used $34,256 of cash for operations. At June 30, 2026, the Company had an accumulated deficit of $482,578. Cash, cash equivalents, and marketable securities were $79,431 as of June 30, 2026. Management expects to incur substantial additional operating losses for the next several years and may need to obtain additional debt or equity financings in order to complete development of its products, obtain regulatory approvals, launch and commercialize its products.

Liquidity and Going Concern

Management has determined that the Company’s current available cash, cash equivalents and marketable securities may not be sufficient to fund its planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to the Company’s ability to continue as a going concern.

The Company’s ability to continue as a going concern will depend on, among other things, its ability to obtain additional funding and appropriately manage the amount of cash used to fund its operations. The Company plans to address this condition through public or private equity, convertible or debt financing or capital obtained in connection with strategic collaborations or licensing or other sources. There are inherent uncertainties as the outcome of these potential transactions are outside management’s control, and therefore there are no assurances that any of these potential transactions will occur. In addition, there can be no assurances that these transactions will sufficiently improve the Company’s liquidity or that the Company will otherwise realize the anticipated benefits. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, suspend or curtail planned programs, or pursue strategic alternatives. Any of these actions could materially harm the Company’s business, results of operations and future prospects.

The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the unaudited condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

 

2. Summary of Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2025, included in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 6, 2026. Since the date of those consolidated financial statements, there have been no changes to its significant accounting policies.

5


PMV Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share amounts)

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the interim period reporting requirements of Form 10-Q and Article 10 of Regulation S-X. The condensed consolidated balance sheet as of June 30, 2026, the condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of stockholders’ equity and condensed consolidated statements of cash flows for the three and six months ended June 30, 2026 and 2025 are unaudited, but, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for any interim period are not necessarily indicative of results for the year ending December 31, 2026, or for any other subsequent interim period. The condensed consolidated balance sheet as of December 31, 2025, has been derived from the Company’s audited consolidated financial statements.

The accompanying condensed consolidated financial statements include the Company’s accounts and the accounts of its wholly owned subsidiary, PMV Pharma Australia Pvt Ltd. All significant intercompany transactions and balances have been eliminated upon consolidation. These condensed consolidated financial statements are presented in United States (“U.S.”) Dollars, which is also the functional currency of the Company.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development costs, accrued research and development costs and related prepaid expenses, and stock-based compensation. Actual results could differ materially from those estimates.

Fair Value of Financial Instruments

The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:

•
Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
•
Level 2 - Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.
•
Level 3 - Inputs are unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions that are unobservable.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

Cash, Cash Equivalents, and Marketable Securities

Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents.

The Company’s marketable debt securities have been classified and accounted for as available-for-sale. The Company classifies its marketable debt securities as either short-term or long-term based on each instrument’s underlying contractual

6


PMV Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share amounts)

maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. The Company’s marketable debt securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in stockholders’ equity. Premiums and discounts on marketable debt securities are amortized into earnings over the life of the security and recorded on the interest income, net line of the income statement. For the six months ended June 30, 2026 and 2025, the Company recorded $767 and $1,564 of accretion, respectively.

Property and Equipment

Property and equipment are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight‑line method over the estimated useful lives of the assets, generally five years, except for leasehold improvements, which are amortized over the shorter of the useful life of the asset or the remaining term of the lease. Upon retirement or sale of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Repairs and maintenance costs are charged to operations as incurred.

 

Comprehensive Loss and Accumulated Other Comprehensive Income (Loss)

Other comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation gains and losses.

Leases

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset’s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (“ROU”) assets and operating lease liabilities at the lease commencement date, and thereafter if modified. The lease term includes any renewal options that the Company is reasonably certain to exercise. The Company’s policy is to not record leases with a lease term of 12 months or less on its balance sheets. The Company's only existing lease recorded on the balance sheet is for office space.

The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.

Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations.

Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company’s share of the lessor’s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Variable payments have been excluded from the lease liability and associated right-of-use asset. Neither of the Company’s leases contain residual value guarantees.

The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash, cash equivalents, and marketable securities. Cash and cash equivalents were held at primarily two financial institutions. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash

7


PMV Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share amounts)

and cash equivalents. The Company’s marketable securities are carried at fair value and include any unrealized gains and losses. Any investments with unrealized losses are considered to be temporarily impaired.

The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, cost of development, uncertainty of market acceptance of the product, competition from substitute products and larger companies, protection of proprietary technology, any future strategic relationships and dependence on key individuals.

Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company’s product candidates will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or it is unable to maintain clearance, it could have a materially adverse impact on the Company.

Recently Adopted Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amended guidance enhances income tax disclosures primarily related to the effective tax rate reconciliation and income taxes paid information. This guidance requires disclosure of specific categories in the effective tax rate reconciliation and additional information on reconciling items meeting a quantitative threshold. In addition, the amended guidance requires disaggregating income taxes paid (net of refunds received) by federal, state, and foreign taxes. It also requires disaggregating individual jurisdictions in which income taxes paid (net of refunds received) are equal to or greater than 5 percent of total income taxes paid (net of refunds received). The amended guidance is effective for annual periods beginning after December 15, 2024. The Company adopted this guidance prospectively for the annual period ending December 31, 2025. For additional information, see “Note 9 — Income Taxes.”

Recent Accounting Pronouncements Not Yet Adopted

In November 2024, the FASB issued ASU 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses”. This amended guidance requires disaggregation of specific expense categories in the notes to the financial statements and a qualitative description of the remaining expense amounts not separately disaggregated. This standard becomes effective for reporting companies with annual reporting periods beginning after December 15, 2026, and requires prospective application with an option to apply it retrospectively. The Company anticipates adopting this standard in its Annual Report on Form 10-K for the year ending December 31, 2027. The Company is currently evaluating the impact that the adoption of this standard will have on its condensed consolidated financial statements.

In September 2025, the FASB issued ASU 2025-07 (“ASU 2025-07”), Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606). The guidance refines the scope of Topic 815 to clarify which contracts are subject to derivative accounting. The guidance also provides clarification under Topic 606 for share-based payments from a customer in a revenue contract. The amendments in ASU 2025-07 are effective for fiscal years beginning after December 15, 2026, and interim reporting periods, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its condensed consolidated financial statements.

 

3. Fair Value Measurements

The Company’s financial instruments consist of money market funds, U.S. government debt securities and corporate debt securities. Cash and cash equivalents includes money market funds, corporate securities, and government securities, which are measured at fair value on a recurring basis using quoted prices and are classified as Level 1. Marketable securities are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified

8


PMV Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share amounts)

as Level 2 inputs, except for investments in U.S. treasury securities and certificates of deposit which are classified as Level 1. There were no Level 3 assets or liabilities at June 30, 2026.

The following tables show the Company’s cash equivalents and available-for-sale securities’ carrying amounts and fair values as of June 30, 2026, and December 31, 2025:

 

 

 

As of June 30, 2026

 

 

 

Carrying
Amount

 

 

Gross Unrealized Gains

 

 

Gross Unrealized Losses

 

 

Fair
Value

 

 

Quoted
priced in
active
markets
(Level 1)

 

 

Significant
other
observable
inputs
(Level 2)

 

 

Significant
unobservable
inputs
(Level 3)

 

Financial assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

12,436

 

 

$

—

 

 

$

—

 

 

$

12,436

 

 

$

12,436

 

 

$

—

 

 

$

—

 

Corporate securities

 

 

44,867

 

 

 

—

 

 

 

(65

)

 

 

44,802

 

 

 

—

 

 

 

44,802

 

 

 

—

 

Government securities

 

 

22,186

 

 

 

1

 

 

 

(27

)

 

 

22,160

 

 

 

22,160

 

 

 

—

 

 

 

—

 

Total financial assets

 

$

79,489

 

 

$

1

 

 

$

(92

)

 

$

79,398

 

 

$

34,596

 

 

$

44,802

 

 

$

—

 

 

 

 

 

As of December 31, 2025

 

 

 

Carrying
Amount

 

 

Gross Unrealized Gains

 

 

Gross Unrealized Losses

 

 

Fair
Value

 

 

Quoted
Priced in
Active
Markets
(Level 1)

 

 

Significant
Other
Observable
Inputs
(Level 2)

 

 

Significant
Unobservable
Inputs
(Level 3)

 

Financial assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

29,909

 

 

$

—

 

 

$

—

 

 

$

29,909

 

 

$

29,909

 

 

$

—

 

 

$

—

 

Corporate securities

 

 

30,636

 

 

 

12

 

 

 

(4

)

 

 

30,644

 

 

 

—

 

 

 

30,644

 

 

 

—

 

Government securities

 

 

52,229

 

 

 

68

 

 

 

—

 

 

 

52,297

 

 

 

52,297

 

 

 

—

 

 

 

—

 

Total financial assets

 

$

112,774

 

 

$

80

 

 

$

(4

)

 

$

112,850

 

 

$

82,206

 

 

$

30,644

 

 

$

—

 

 

 

Cash Equivalents — As of June 30, 2026, the Company had aggregate cash and cash equivalents of $12,469, including cash equivalents of $12,436, consisting of money market funds and government securities. As of December 31, 2025, the Company had aggregate cash and cash equivalents of $37,983, including cash equivalents of $29,909, consisting of money market funds, and $7,981 in corporate securities.

Marketable Securities — Marketable securities of $66,962 as of June 30, 2026, consisted of corporate debt securities of $44,802 and government debt securities of $22,160. All marketable securities were classified as current, and the Company held no noncurrent marketable securities, as of June 30, 2026. Marketable securities of $74,960 as of December 31, 2025, consisted of corporate debt securities of $22,663 and government debt securities of $52,298. There were $74,960 of current marketable
securities and
no noncurrent marketable securities as of December 31, 2025.

As of June 30, 2026, and December 31, 2025, aggregated gross unrealized losses of available-for-sale investments were not material, and accordingly, no allowance for credit losses was recorded.

4. Property and Equipment, Net

 

 

 

June 30,
2026

 

 

December 31,
2025

 

Machinery & equipment

 

$

1,428

 

 

$

1,447

 

Computers

 

 

13

 

 

 

13

 

Furniture & fixtures

 

 

23

 

 

 

23

 

Leasehold improvements

 

 

45

 

 

 

81

 

Total property and equipment

 

 

1,509

 

 

 

1,564

 

Less: Accumulated depreciation

 

 

(1,355

)

 

 

(1,327

)

Property and equipment, net

 

$

154

 

 

$

237

 

 

 

 

9


PMV Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share amounts)

Depreciation expense for the three months ended June 30, 2026 and 2025 was $24 and $32, respectively. Depreciation expense for the six months ended June 30, 2026 and 2025 was $58 and $69, respectively.

5. Accrued Expenses

Accrued expenses consist of the following:

 

 

June 30,
2026

 

 

December 31,
2025

 

Accrued compensation

 

$

3,203

 

 

$

4,532

 

Accrued research and development costs

 

 

4,865

 

 

 

3,130

 

Accrued legal and professional services

 

 

263

 

 

 

195

 

Total

 

$

8,331

 

 

$

7,857

 

 

6. Commitments and Contingencies

Operating Leases

In January 2021, the Company signed a lease for 50,581 square feet of office and laboratory space (the “One Research Way Lease”) at One Research Way in Princeton, New Jersey (the “Premises”). The lease term initially extended through 2032, had a five-year extension option, and replaced the Company’s two prior facilities as the Company’s headquarters in March 2023. The Company estimated that payments under the One Research Way Lease would be $19,889 through May 2032. The Company received a lease incentive of $4,046 from the lessor for a buildout of laboratory, vivarium, and office space. Management estimated the timing and amounts of reimbursements and included them as a reduction of lease payments when initially measuring the lease liability and right-of-use asset upon commencement. Since the inception date of the lease, $4,046 reimbursements were received from the lessor.

In August 2024, the Company entered into a Lease Termination Agreement with BMR-One Research Way LLC (the “Landlord”), in connection with the termination of the One Research Way Lease (the “Termination Agreement”). The Termination Agreement was contingent on the sale of the Premises by the Landlord to a prospective new buyer, which was met on October 1, 2024, and, as a result, there was no modification in August 2024.

Pursuant to the Termination Agreement, the Company surrendered the Premises in October 2024 and paid a total termination fee of approximately $1,420, consisting of (i) a cash payment in the amount of approximately $798 and (ii) a release of a security deposit from the Company’s existing letter of credit in the amount of approximately $622. The transaction was accounted for as an immediate termination of an operating lease before the expiration of the lease term in accordance with ASC 842. The Company derecognized the lease-related asset and liability resulting in a gain of $4,850. Since the termination fee of $1,420 was not already included in the lease payments, the termination fee was recognized as a loss on termination of the lease. Further, the Company abandoned and wrote-off all the related leasehold improvements totaling $9,454 held at the Premises. This net activity totaling $6,024 was recorded as a loss within General and Administrative expense in the Statement of Operations for the year ended December 31, 2024.

In August 2024, the Company signed a sublease for 14,201 square feet of office space at 400 Alexander Park Drive, Suite 301, in Princeton, New Jersey, to be used as its new headquarters (the “400 Alexander Sublease”). The 400 Alexander Sublease commenced on October 1, 2024 and extends until February 28, 2027. Payment under the 400 Alexander Sublease will total $789 through February 2027.

In September 2024, the Company signed a sublease agreement for 3,205 square feet of office and laboratory space at 311 Pennington Rocky Hill Road in Hopewell, New Jersey (the “311 Pennington Sublease”). The Company utilized the premises as laboratory space for research and development activities. The term of the 311 Pennington Sublease extended through 2029 and provided the Company with the option to extend the term for an additional three year period. Payment under the 311 Pennington Sublease totaled $192 through February 2026.

In March 2026, the 311 Pennington Sublease was terminated effective March 4, 2026, upon the termination of the primary lease between the master landlord and the tenant, in accordance with the terms of the sublease agreement. As a result, the Company accounted for the 311 Pennington Sublease termination as an immediate termination of an operating lease before the expiration of the lease term in accordance with ASC 842. Upon termination, the Company derecognized the related operating lease right‑of‑use asset and lease liabilities and recorded a net gain of approximately $24, which was recognized in General and Administrative expense in the accompanying Statement of Operations for the three months ended March 31, 2026.

10


PMV Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share amounts)

The components of lease cost for the three and six months ended June 30, 2026 and 2025, were as follows:

 

 

 

Three Months Ended June 30,

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Operating lease cost

 

$

82

 

 

$

118

 

 

 

187

 

 

 

235

 

Variable lease cost

 

 

1

 

 

 

18

 

 

 

21

 

 

 

34

 

Short-term lease cost

 

 

75

 

 

 

—

 

 

 

100

 

 

 

—

 

Total lease cost

 

$

158

 

 

$

136

 

 

$

308

 

 

$

269

 

 

 

Amounts reported in the balance sheet for leases where the Company is the lessee as of June 30, 2026, and December 31, 2025, are as follows:

 

Operating Leases

 

June 30,
2026

 

 

December 31,
2025

 

Right-of-use assets, operating leases

 

$

209

 

 

$

801

 

 

 

 

 

 

 

Operating lease liabilities, current

 

$

217

 

 

$

403

 

Operating lease liabilities, non-current

 

 

-

 

 

 

435

 

Total operating lease liabilities

 

$

217

 

 

$

838

 

 

 

 

 

 

 

Weighted-average remaining lease term (years)

 

 

0.67

 

 

 

2.76

 

Weighted-average discount rate

 

 

13.70

%

 

 

13.70

%

 

 

Other information related to leases for the six months ended June 30, 2026 and 2025, respectively, are as follows:

 

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

Net cash paid for amounts included in the measurement of lease liabilities

 

$

193

 

 

$

240

 

Leased assets (derecognized) in exchange for new or modified operating lease liabilities

 

 

(432

)

 

 

(170

)

 

 

Future minimum lease payments, net of reimbursements, remaining as of June 30, 2026, under operating leases by fiscal year were as follows:

 

Fiscal year

 

 

 

2026

 

$

169

 

2027

 

 

56

 

2028

 

 

 

2029

 

 

 

Thereafter

 

 

 

Total minimum lease payments

 

$

225

 

Less: Amounts representing imputed interest

 

 

(8

)

Present value of lease liabilities

 

$

217

 

 

 

Rent expense recorded during the three months ended June 30, 2026 and 2025 was $157 and $118, respectively. Rent expense recorded during the six months ended June 30, 2026 and 2025 was $287 and $235, respectively.

Contingencies

From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when future expenditures are probable and such expenditures can be reasonably estimated.

11


PMV Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share amounts)

7. Stockholders’ Equity

The Company is authorized to issue up to 1,000,000,000 shares of common stock with a par value of $0.00001 per share and 5,000,000 shares of preferred stock with a par value of $0.00001 per share. At June 30, 2026 and December 31, 2025, there were 53,460,432 and 53,331,766 shares of common stock issued and outstanding, respectively.

Common stockholders are entitled to receive dividends if and when declared by the board of directors subject to the rights of any preferred stockholders. As of June 30, 2026, no dividends on common stock had been declared by the Company.

ATM Program

On October 4, 2021, the Company entered into an at-the-market offering program (the “ATM Program”). Pursuant to the ATM Program, the Company may offer and sell shares of its common stock having aggregate gross sales proceeds of up to $150.0 million from time to time. During the three and six months ended June 30, 2026, the Company did not sell any shares of its common stock under the ATM Program. As of June 30, 2026, the Company has approximately $113.8 million remaining in gross proceeds available for future issuances of common stock under the ATM Program.

8. Stock Plan

2020 Equity Incentive Plan

The 2020 Equity Incentive Plan (the “2020 Plan”) was approved by the Company’s board of directors on September 24, 2020. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The number of shares of common stock initially reserved for issuance under the 2020 Plan was 4,406,374, which shall be increased, upon approval by the Company’s board of directors, on January 1, 2021 and each January 1 thereafter, in an amount equal to the least of (i) 4,406,374 shares of common stock, (ii) five percent (5%) of the outstanding common stock on the immediately preceding December 31, or (iii) such number of common stock determined by the board of directors no later than the immediately preceding December 31. For 2026, the compensation committee of the Company’s board of directors, as the 2020 Plan administrator, exercised its discretion under clause (ii) to increase the number of shares of common stock reserved for issuance under the 2020 Plan by 2,666,470 shares, effective as of January 1, 2026. As of June 30, 2026, there were 3,185,748 shares available for issuance under the 2020 Plan.

On January 18, 2024, the Company granted 952,665 RSUs to employees VP-level or higher, pursuant to an employee retention program approved by the compensation committee of the Company’s board of directors. As of June 30, 2025 such RSUs were fully vested and common stock was issued upon settlement of the RSUs.

2020 Employee Stock Purchase Plan

The 2020 Employee Stock Purchase Plan (the “2020 ESPP”) was approved by the Company’s board of directors on September 24, 2020. A total of 400,752 shares of common stock were initially reserved for issuance under this plan, which shall be increased, upon approval by the Company’s board of directors, on January 1, 2021 and each January 1 thereafter, to the lesser of (i) 801,504 shares of common stock, (ii) 1% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (iii) an amount determined by the board of directors or any of its committees no later than the last day of the immediately preceding fiscal year. For 2026, the Company’s board of directors waived the annual increase to the shares reserved under the 2020 ESPP. As of June 30, 2026, 740,081 shares are issued or outstanding, and there were 1,033,530 shares available for issuance, under the 2020 ESPP.

Stock Options

On July 16, 2024, the Company filed with the Securities and Exchange Commission a Tender Offer Statement on Schedule TO defining the terms and conditions of a one-time voluntary stock option exchange to its employees of certain options to purchase up to an aggregate of 2,820,491 shares of the Company’s common stock (the “Option Exchange”). On August 13, 2024, the completion date of the Option Exchange, stock options covering an aggregate of 2,786,691 shares of common stock were tendered by eligible employees, and the Company granted new options at an exercise price of $1.48, the Company’s closing stock price on August 13, 2024, covering an aggregate of 2,786,691 shares of common stock under the 2020 Plan in exchange for the tendered options. The new options are subject to a new three or four-year vesting schedule,

12


PMV Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share amounts)

vesting in equal annual installments over the vesting term. Each new option has a maximum term of ten years. The Option Exchange was treated as a modification for accounting purposes. As a result of the Option Exchange, the Company will recognize incremental stock-based compensation expense of $1,370 over the requisite service period of the new stock options, which is three or four years. The Company will recognize the sum of the incremental stock-based compensation expense and the remaining unrecognized compensation expense for the original awards on the modification date, over the requisite service period of the new stock options.

The following table summarizes option activity for the six-month period ended June 30, 2026:

 

 

 

Options Outstanding

 

 

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

 

Weighted

 

 

Average

 

 

Aggregate

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Intrinsic

 

 

 

Number of

 

 

Exercise

 

 

Contractual Life

 

 

Value

 

 

 

Options

 

 

Price

 

 

(in years)

 

 

(in 000s)

 

Balances at December 31, 2025

 

 

11,990,688

 

 

$

2.43

 

 

 

7.74

 

 

$

86

 

Options granted

 

 

3,898,665

 

 

$

1.51

 

 

 

 

 

 

 

Options forfeited / cancelled

 

 

(79,818

)

 

$

1.70

 

 

 

 

 

 

 

Options exercised

 

 

—

 

 

 

—

 

 

 

 

 

 

 

Balances June 30, 2026 (unaudited)

 

 

15,809,535

 

 

$

2.21

 

 

 

7.83

 

 

$

218

 

At June 30, 2026

 

 

 

 

 

 

 

 

 

 

 

 

Vested and expected to vest

 

 

15,809,535

 

 

$

2.21

 

 

 

7.83

 

 

$

218

 

Exercisable

 

 

7,191,393

 

 

$

3.06

 

 

 

6.58

 

 

$

110

 

 

 

At June 30, 2026, the total compensation cost related to nonvested awards not yet recognized was $12,278. The weighted-average period over which the nonvested awards is expected to be recognized was 2.7 years.

The Company estimated the fair value of the options using the Black-Scholes options valuation model. The fair value of the options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value was estimated using the following assumptions:

 

 

 

For the Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

Risk-free interest rate

 

 

3.82% - 4.27%

 

 

 

3.89% - 4.48%

 

Expected life (in years)

 

 

5.50 - 6.25

 

 

 

5.50 - 6.25

 

Dividend yield

 

 

0%

 

 

 

0%

 

Expected volatility

 

 

77.29% - 77.77%

 

 

 

78.67% - 80.22%

 

 

 

The weighted average assumptions used to estimate the fair value of stock purchase rights under the ESPP are as follows:

 

 

 

For the Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

Risk-free interest rate

 

 

3.75%

 

 

 

4.33%

 

Expected life (in years)

 

 

0.50

 

 

 

0.50

 

Dividend yield

 

 

0%

 

 

 

0%

 

Expected volatility

 

 

77.77%

 

 

 

78.67%

 

 

 

Risk Free Interest Rate: The risk-free rate is based on the U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected term of the option.

Expected Term: The Company uses the simplified method to calculate expected term described in the SEC’s Staff Accounting Bulletin No. 107, which takes into account vesting term and expiration date of the options.

Dividend Yield: The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model.

Volatility: Volatility is based on the historical volatility of the Company’s publicly traded shares for the expected term.

13


PMV Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share amounts)

Restricted Stock Units

For the quarter ending June 30, 2026, no RSU awards were granted, vested, or unvested. As of June 30, 2026 there was no unrecognized compensation cost related to RSUs that are expected to vest.

 

 

 

Stock-based compensation expense recorded under ASC 718 related to stock options granted and common stock issued under the 2020 ESPP were allocated to research and development and general and administrative expense as follows:

 

 

 

For the Three Months Ended June 30,

 

 

For the Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Research and development

 

$

697

 

 

$

741

 

 

$

1,335

 

 

$

1,377

 

General and administrative

 

 

846

 

 

 

927

 

 

 

1,600

 

 

 

1,799

 

Total stock-based compensation

 

$

1,543

 

 

$

1,668

 

 

$

2,935

 

 

$

3,176

 

 

 

Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:

 

 

 

For the Three Months Ended June 30,

 

 

For the Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Stock options

 

$

1,510

 

 

$

1,341

 

 

$

2,870

 

 

$

2,516

 

Restricted stock units

 

 

—

 

 

 

281

 

 

 

—

 

 

 

559

 

Employee stock purchase plan

 

 

33

 

 

 

46

 

 

 

65

 

 

 

101

 

Total stock-based compensation

 

$

1,543

 

 

$

1,668

 

 

$

2,935

 

 

$

3,176

 

 

9. Income Taxes

The Company’s effective tax rates were 0% and 0% for the three months ended June 30, 2026 and 2025, respectively.

During the three and six months ended June 30, 2026 and 2025, the Company recorded a full valuation allowance on federal and state net deferred tax assets since management does not forecast the Company to be in a taxable position in the near future.

The State of New Jersey’s Technology Business Tax Certificate Program allows certain high technology and biotechnology companies to sell unused net-operating loss (“NOL”) carryforwards and R&D tax credits to other New Jersey-based corporate taxpayers. For the six months ended June 30, 2025, we received a benefit for income taxes of $2,196. As of June 30, 2025, the Company received $18,372 of cash for the NOL and R&D tax credit sales related to the tax years ended December 31, 2015 to 2023. For the six months ended June 30, 2026, the Company did not receive any benefit for income taxes.

 

10. Net Loss per Share

The Company excluded all outstanding stock options and RSUs at each period end from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect. The following common stock equivalents were excluded from the calculation of diluted net loss per share:

 

 

 

As of June 30,

 

 

 

2026

 

 

2025

 

Options to purchase common stock

 

 

15,809,535

 

 

 

12,211,331

 

Expected shares to be purchased under 2020 ESPP

 

 

6,845

 

 

 

6,845

 

Total

 

 

15,816,380

 

 

 

12,218,176

 

 

14


PMV Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share amounts)

 

11. Related Parties

The Company has consulting agreements with two members of its board of directors. Total consulting fees paid during the three months ended June 30, 2026 and 2025 were $30 and $50, respectively. Total consulting fees paid during the six months ended June 30, 2026 and 2025 were $60 and $100, respectively. There were no amounts owed under the consulting agreements as of June 30, 2026.

 

12. Segment Information

The Company has viewed its operations and manages its business as one operating and reporting segment. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the Company’s CODM to make decisions with respect to resource allocation and assessment of performance. The Company’s CODM is its Chief Executive Officer (the “CEO”), who reviews and evaluates consolidated net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods. The determination of a single segment is consistent with the financial information regularly reviewed by the CEO.

The CEO regularly reviews the condensed consolidated statement of operations and a disaggregation of operating expenses, of which the significant expenses are related to research and development. The following table represents the significant segment expenses regularly provided to the CEO:

 

 

 

For the Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

Research and Development

 

 

 

 

 

 

Research

 

$

1,487

 

 

$

2,571

 

Development

 

 

19,350

 

 

 

24,875

 

Personnel related

 

 

7,834

 

 

 

7,018

 

Stock-based compensation

 

 

1,335

 

 

 

1,377

 

Total research and development

 

 

30,006

 

 

$

35,841

 

General and administration

 

 

 

 

 

 

Personnel related

 

$

2,992

 

 

$

2,896

 

Stock-based compensation

 

 

1,600

 

 

 

1,799

 

External

 

 

3,302

 

 

 

3,905

 

Total general and administrative

 

 

7,894

 

 

 

8,600

 

Loss from Operations

 

$

37,900

 

 

$

44,441

 

 

13. Subsequent Event

The Company has evaluated subsequent events through August 14, 2026, the date these financial statements were issued. The Company determined that there were no subsequent events that required adjustment to or disclosure in the financial statements.

15


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the related notes and other financial information included in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and notes thereto as of and for the years ended December 31, 2025 and 2024 and the related “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” including “Contractual Obligations and Commitments” and “Critical Accounting Policies and Estimates,” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission, or the SEC, on March 6, 2026. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “we,” “us,” and “our” refer to PMV Pharmaceuticals, Inc.

In addition to historical information, this Quarterly Report on Form 10-Q contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including but not limited to those set forth under the captions “Special Note Regarding Forward-Looking Statements,” “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as updated by our subsequent filings under the Securities Exchange Act of 1934, as amended. Furthermore, past operating results are not necessarily indicative of results that may occur in future periods.

Overview

We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the “guardian of the genome,” and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. We have leveraged more than four decades of research experience and developed unique insights into p53 to create a precision oncology platform designed to generate selective, small molecule, tumor-agnostic therapies that structurally correct specific mutant p53 proteins to restore their wild-type function. We are deploying our precision oncology platform to target p53 mutations and other p53-related cancers.

Since our formation in March 2013, we have devoted substantially all of our time and efforts to performing research and development activities, advancing our lead product candidate toward regulatory approval, and raising capital. We are not profitable and have incurred losses in each year since our inception. During the three and six months ended June 30, 2026, we incurred net losses of $18.1 million and $36.1 million, respectively. As of June 30, 2026, we had an accumulated deficit of $482.6 million. We do not currently have any product candidates approved for sale, and we continue to incur significant research and development and general and administrative expenses related to our operations. We initiated a Phase 1/2 clinical trial, PYNNACLE, in October 2020 for our lead product candidate, rezatapopt. Our strategy is to seek approval under an accelerated pathway, and we believe the Phase 2 portion of the PYNNACLE clinical trial has the potential to serve as a pivotal study. In October 2020, we were granted FDA Fast Track designation of rezatapopt for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation. In July 2023, we met with the FDA at an End of Phase 1 meeting where alignment was obtained on the recommended Phase 2 dose and key elements of the single arm, Phase 2 registrational portion of the PYNNACLE study. In October 2023, we presented our updated Phase 1 clinical data for rezatapopt at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Annual Meeting. We dosed our first patient in the pivotal Phase 2 monotherapy portion of the PYNNACLE study in the first quarter of 2024. In September 2025, we announced interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial, which was updated in October 2025 in a late-breaking oral presentation and poster presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Meeting. In March 2026, rezatapopt was granted Orphan Drug Designation, or ODD, from the FDA for the treatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. In April 2026, we presented interim ovarian cancer data from the Phase 2 pivotal portion of the PYNNACLE clinical trial, in an oral presentation at the 2026 Society of Gynecologic Oncology Meeting. Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the study has been completed. We plan to submit our initial New Drug Application, or NDA, via accelerated approval for platinum resistant/refractory ovarian cancer in the first quarter of 2027.

We expect that our operating expenses will increase significantly as we advance our product candidates through preclinical and clinical development, seek regulatory approval, and prepare for and, if approved, proceed to commercialization; acquire, discover, validate, and develop additional product candidates; obtain, maintain, protect, and enforce our intellectual property portfolio; and hire additional personnel. We expect to continue to incur significant losses for the foreseeable future.

 

16


 

Our ability to generate product revenue will depend on the successful development, regulatory approval, and eventual commercialization of one or more of our product candidates. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through private or public equity or debt financings, collaborative, or other arrangements with corporate sources, or through other sources of financing. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of our product candidates.

Management has determined that our current available cash, cash equivalents and marketable securities may not be sufficient to fund our planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to our ability to continue as a going concern. For additional information, see “Note 1 — Formation and Business of the Company— Liquidity and Going Concern.”

We plan to continue to use third-party service providers, including clinical research organizations, or CROs, and contract manufacturing organizations, or CMOs, to carry out our preclinical and clinical development and to manufacture and supply the materials to be used during the development and commercialization of our product candidates. We do not currently have a sales force or commercial infrastructure, and we will need to develop these capabilities, or contract with third parties to perform these functions, to commercialize any product candidate that receives regulatory approval.

 

Components of Results of Operations

Revenue

To date, we have not generated any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, or result in license agreements with third parties, we may generate revenue in the future from product sales or license agreements. However, there can be no assurance as to when we will generate such revenue, if at all.

Operating Expenses

Research and Development Expenses

Our research and development expenses consist primarily of costs incurred to conduct research, such as the discovery and development of our product candidates as well as the development of future product candidates. Research and development expenses include personnel costs, including stock-based compensation expense, third-party contractor services, and depreciation and maintenance of research equipment. We expense research and development costs as they are incurred.

We do not allocate our costs by product candidate or development program, as a significant amount of research and development expenses include compensation costs, materials, supplies, depreciation on and maintenance of research equipment, and the cost of services provided by outside contractors, which are not tracked by product candidate or development program. In particular, with respect to internal costs, several of our departments support multiple product candidate research and development programs, and therefore the costs cannot be allocated to a particular product candidate or development program. Substantially all of our research and development costs are associated with our lead product candidate, rezatapopt. We initiated our Phase 1/2 PYNNACLE clinical trial in October 2020, and on that date, we were granted FDA Fast Track designation of rezatapopt for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation. In October 2023, we presented our updated Phase 1 clinical data for rezatapopt at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Meeting. In September 2025, we announced interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial, which was updated in October 2025 in a late-breaking oral presentation and poster presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Meeting. In March 2026, rezatapopt was granted ODD from the FDA for the treatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the study has been completed. We plan to submit our initial New Drug Application, or NDA, via accelerated approval for platinum resistant/refractory ovarian cancer in the first quarter of 2027.

We expect to continue to incur substantial research and development expenses in the future as we advance our product candidates into and through clinical trials and pursue regulatory approval of our product candidates. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected by a variety of factors including: the safety and efficacy of our product candidates, clinical data, investment in our clinical program, the ability of any future collaborators to successfully develop our licensed product candidates, competition, manufacturing capability, and commercial viability. We may never succeed in achieving

17


 

regulatory approval for any of our product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects.

General and Administrative Expenses

General and administrative expenses include personnel costs, expenses for outside professional services and other allocated expenses. Personnel costs consist of salaries, bonuses, benefits, and stock-based compensation. Outside professional services consist of legal, accounting and audit services and other consulting fees. Allocated expenses consist of rent expense related to our office and research and development facilities. We have incurred expenses related to compliance with the rules and regulations of the SEC, and those of any national securities exchange on which our securities are traded, additional insurance expenses, investor relations activities and other administrative and professional services. We also expect to increase our general and administrative expenses as we advance our product candidates through preclinical research and development, manufacturing, clinical development, and commercialization.

Interest Income, Net

Interest income, net, primarily consists of interest income from our interest-bearing cash, cash equivalents, and marketable securities, and interest costs related to accretion and amortization of discounts and premiums on marketable securities.

Results of Operations

Comparison of the Three Months ended June 30, 2026 and 2025

The following table summarizes our results of operations (in thousands):

 

 

 

Three Months Ended
June 30,

 

 

 

 

Statement of operations data:

 

2026
(Unaudited)

 

 

2025
(Unaudited)

 

 

Change

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

$

14,676

 

 

$

18,400

 

 

$

(3,724

)

General and administrative

 

 

4,205

 

 

 

4,479

 

 

 

(274

)

 

 

 

 

 

 

 

 

 

Total operating expenses

 

 

18,881

 

 

 

22,879

 

 

 

(3,998

)

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(18,881

)

 

 

(22,879

)

 

 

3,998

 

Other income (expense):

 

 

 

 

 

 

 

 

 

Interest income, net

 

 

788

 

 

 

1,690

 

 

 

(902

)

Other income (expense), net

 

 

10

 

 

 

(16

)

 

 

26

 

 

 

 

 

 

 

 

 

 

Total other income (expense)

 

 

798

 

 

 

1,674

 

 

 

(876

)

 

 

 

 

 

 

 

 

 

Loss before (benefit) provision for income taxes

 

 

(18,083

)

 

 

(21,205

)

 

 

3,122

 

Provision (benefit) for income taxes

 

 

3

 

 

 

5

 

 

 

(2

)

 

 

 

 

 

 

 

 

 

Net loss

 

$

(18,086

)

 

$

(21,210

)

 

$

3,124

 

 

Research and Development Expenses

The following table summarizes our research and development expenses incurred during the periods indicated (in thousands):

 

18


 

 

 

Three Months Ended
June 30,

 

 

 

 

Statement of operations data:

 

2026
(Unaudited)

 

 

2025
(Unaudited)

 

 

Change

 

Research

 

$

478

 

 

$

1,347

 

 

$

(869

)

Development

 

 

9,612

 

 

 

12,865

 

 

 

(3,253

)

Personnel related

 

 

3,889

 

 

 

3,447

 

 

 

442

 

Stock-based compensation

 

 

697

 

 

 

741

 

 

 

(44

)

Total

 

$

14,676

 

 

$

18,400

 

 

$

(3,724

)

 

 

Research and development expenses were $14.7 million for the three months ended June 30, 2026, compared to $18.4 million for the three months ended June 30, 2025. The decrease of $3.7 million, compared to the three months ended June 30, 2025, was primarily due to the following:

 

•
$4.1 million decrease in research and development expenses largely driven by decreased contract research organization costs for advancing our lead product candidate, rezatapopt; offset by
•
$0.5 million increase in personnel related costs.

General and Administrative Expenses

General and administrative expenses were $4.2 million for the three months ended June 30, 2026, compared to $4.5 million for the three months ended June 30, 2025. The decrease of $0.3 million, compared to the three months ended June 30, 2025, was primarily due to the following:

•
$0.1 million decrease in personnel expenses driven by a decrease in stock-based compensation costs and $0.2 million decrease in finance support costs.

Interest Income, Net

Interest income, net primarily consists of interest income from our interest-bearing cash, cash equivalents, and marketable securities and interest costs related to accretion and amortization of discounts and premiums on marketable securities. Interest income, net was $0.8 million for the three months ended June 30, 2026, compared to $1.7 million for the three months ended June 30, 2025. The decrease of $0.9 million was driven by decreased average invested balances in marketable securities and U.S. treasuries during the three months ended June 30, 2026.

19


 

Comparison of the Six Months ended June 30, 2026 and 2025

The following table summarizes our results of operations (in thousands):

 

 

Six Months Ended
June 30,

 

 

 

 

Statement of operations data:

 

2026
(Unaudited)

 

 

2025
(Unaudited)

 

 

Change

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

$

30,006

 

 

$

35,841

 

 

$

(5,835

)

General and administrative

 

 

7,894

 

 

 

8,600

 

 

 

(706

)

 

 

 

 

 

 

 

 

 

Total operating expenses

 

 

37,900

 

 

 

44,441

 

 

 

(6,541

)

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(37,900

)

 

 

(44,441

)

 

 

6,541

 

Other income (expense):

 

 

 

 

 

 

 

 

 

Interest income, net

 

 

1,768

 

 

 

3,625

 

 

 

(1,857

)

Other income, net

 

 

11

 

 

 

(21

)

 

 

32

 

 

 

 

 

 

 

 

 

 

Total other income

 

 

1,779

 

 

 

3,604

 

 

 

(1,825

)

 

 

 

 

 

 

 

 

 

Loss before provision for income taxes

 

 

(36,121

)

 

 

(40,837

)

 

 

4,716

 

Income taxes

 

 

3

 

 

 

(2,191

)

 

 

2,194

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(36,124

)

 

$

(38,646

)

 

$

2,522

 

Research and Development Expenses

The following table summarizes our research and development expenses incurred during the periods indicated (in thousands):

 

 

Six Months Ended
June 30,

 

 

 

 

Statement of operations data:

 

2026
(Unaudited)

 

 

2025
(Unaudited)

 

 

Change

 

Research

 

$

1,487

 

 

$

2,571

 

 

$

(1,084

)

Development

 

 

19,350

 

 

 

24,875

 

 

 

(5,525

)

Personnel related

 

 

7,834

 

 

 

7,018

 

 

 

816

 

Stock-based compensation

 

 

1,335

 

 

 

1,377

 

 

 

(42

)

Total

 

$

30,006

 

 

$

35,841

 

 

$

(5,835

)

 

Research and development expenses were $30.0 million for the six months ended June 30, 2026, compared to $35.8 million for the six months ended June 30, 2025. The decrease of $5.8 million, compared to the six months ended June 30, 2025, was primarily due to the following:

•
$6.5 million decrease in research and development expenses largely driven by decreased contract research organization costs for advancing our lead product candidate, rezatapopt; offset by
•
$0.7 million increase in expenses for personnel related costs.

General and Administrative Expenses

General and administrative expenses were $7.9 million for the six months ended June 30, 2026, compared to $8.6 million for the six months ended June 30, 2025. The decrease of $0.7 million, compared to the six months ended June 30, 2025, was primarily due to the following:

•
$0.6 million decrease in finance and legal support costs, and $0.1 million decrease in personnel expenses driven by a decrease in stock-based compensation costs.

Interest Income, Net

Interest income, net primarily consists of interest income from our interest-bearing cash, cash equivalents, and marketable securities and interest costs related to accretion and amortization of discounts and premiums on marketable

20


 

securities. Interest income, net was $1.8 million for the six months ended June 30, 2026, compared to $3.6 million for the six months ended June 30, 2025. The decrease of $1.8 million compared to the six months ended June 30, 2025, was driven by decreased average invested balances in marketable securities and U.S. treasuries during the six months ended June 30, 2026.

Income Tax Benefit

The State of New Jersey’s Technology Business Tax Certificate Program allows certain high technology and biotechnology companies to sell NOL carryforwards and R&D tax credits to other New Jersey-based corporate taxpayers. As of June 30, 2025, we received $18.4 million of cash for the NOL and R&D tax credit sales related to the tax years ended December 31, 2015 to 2023. The sale of the NOLs and R&D tax credits have been recorded as an income tax benefit within the condensed consolidated statement of operations. For the six months ended June 30, 2025, we had reached the sale limit established by the program and received a benefit for income taxes of $2.2 million. We did not receive any benefit for income taxes for the six months ended June 30, 2026.

 

Liquidity and Capital Resources

Our financial condition is summarized as follows (in thousands):

 

 

As of June 30,

 

 

As of December 31,

 

 

 

 

 

 

2026

 

 

2025

 

 

Change

 

Financial assets:

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

12,469

 

 

$

37,983

 

 

$

(25,514

)

Marketable securities – current

 

 

66,962

 

 

 

74,960

 

 

 

(7,998

)

Marketable securities – noncurrent

 

 

—

 

 

 

—

 

 

 

—

 

Total financial assets

 

$

79,431

 

 

$

112,943

 

 

$

(33,512

)

 

 

 

 

 

 

 

 

 

Working capital:

 

 

 

 

 

 

 

 

 

Current assets

 

$

81,409

 

 

$

115,227

 

 

$

(33,818

)

Current liabilities

 

 

10,568

 

 

 

11,415

 

 

 

(847

)

Total working capital

 

$

70,841

 

 

$

103,812

 

 

$

(32,971

)

 

Sources of Liquidity

Since our inception, we have not generated any revenue from any product sales or any other sources and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any of our product candidates. Even if the Company's drug development and commercialization efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. As of June 30, 2026, we had cash, cash equivalents, and marketable securities of $79.4 million and an accumulated deficit of $482.6 million. We have financed our operations primarily through issuance and sales of our equity securities.

On November 20, 2024 we filed a shelf registration statement on Form S-3 (File No. 333-283349) with the SEC and a prospectus supplement, which registered the offering, issuance and sale of up to $200.0 million of various equity and debt securities and up to $113.8 million of common stock pursuant to an at-the-market equity offering program with Jefferies LLC, dated October 4, 2021, or the ATM Program. The SEC declared the registration statement effective on November 27, 2024. During the three and six months ending June 30, 2026, we did not sell any shares of our common stock pursuant to the ATM Program. As of June 30, 2026, we had approximately $113.8 million remaining in gross proceeds available for future issuances of common stock under the ATM Program.

Contractual Obligations and Commitments

We enter into contracts in the normal course of business with CROs and other vendors to assist in the performance of our research and development activities and other services and products for operating purposes. These contracts generally provide for termination on notice, and therefore are cancelable contracts.

In September 2024, we signed two subleases, one for 14,201 square feet of office space at 400 Alexander Park Drive, Suite 301, in Princeton, New Jersey, to be used as our new headquarters, or the 400 Alexander Sublease, and the other for 3,205 square feet of office and laboratory space at 311 Pennington Rocky Hill in Hopewell, New Jersey, to be used for our new laboratory space, or the 311 Pennington Sublease. The 400 Alexander Sublease term extends until February 2027. Amounts

21


 

related to future lease payments for the 400 Alexander Sublease as of June 30, 2026, totaled $0.3 million with $0.3 million to be paid within the next 12 months. In March 2026, the 311 Pennington Sublease was terminated by the sublessor and we recorded a net gain of approximately $24 thousand, which was recognized in General and Administrative expense.

 

Plan of Operation and Future Funding Requirements

We use our capital resources primarily to fund operating expenses, mainly research and development expenditures. At this time, due to the inherently unpredictable nature of preclinical and clinical development, we cannot reasonably estimate the costs we will incur and the timelines that will be required to complete development, obtain marketing approval and commercialize our current product candidates or any future product candidates, if at all. For the same reasons, we are also unable to predict when, if ever, we will generate revenue from product sales or whether, or when, if ever, we may achieve profitability. Clinical and preclinical development timelines, the probability of success, and development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.

Due to our significant research and development expenditures, we have generated substantial operating losses in each period since inception. We have incurred an accumulated deficit of $482.6 million through June 30, 2026. We expect to incur substantial additional losses in the future. For the six months ended June 30, 2026 and 2025, our cash operating expenditures were $34.3 million and $36.6 million, respectively. Based on our research and development plans, we expect that our cash, cash equivalents, and marketable securities as of June 30, 2026 will be sufficient to fund our planned operations through the second quarter of 2027, which is less than one year from the date of this Quarterly Report. As a result, management has determined that there is substantial doubt as to our ability to continue as a going concern.

Our ability to continue as a going concern will depend on, among other things, our ability to obtain additional funding and appropriately manage the amount of cash used to fund our operations. We plan to address this condition through public or private equity, convertible or debt financing or capital obtained in connection with strategic collaborations or licensing or other sources. There are inherent uncertainties as the outcome of these potential transactions are outside management’s control, and therefore there are no assurances that any of these potential transactions will occur. In addition, there can be no assurances that these transactions will sufficiently improve our liquidity or that we will otherwise realize the anticipated benefits. If we are not able to secure adequate additional funding, we may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, suspend or curtail planned programs, or pursue strategic alternatives. Any of these actions could materially harm our business, results of operations and future prospects.

 

We have based this estimate on assumptions that may prove to be wrong, however, and we could use our capital resources sooner than we expect.

The timing and amount of our operating expenditures will depend largely on:

•
the timing and progress of preclinical, clinical development and commercial preparatory activities;
•
the number and scope of preclinical and clinical programs we decide to pursue;
•
the timing and amount of milestone payments we may receive under any future collaboration agreements;
•
our ability to maintain future licenses and research and development programs and to establish new collaboration and/or in-licensing arrangements;
•
the costs involved in prosecuting and enforcing patent and other intellectual property claims;
•
the cost and timing of regulatory approvals; and
•
our efforts to manage our office headquarters, enhance operational systems and hire additional personnel to support development and commercialization of our product candidates and satisfy our obligations as a public company.

 

Until such time, if ever, as we can generate substantial revenue from product sales, we expect to fund our operations and capital funding needs through equity and/or debt financing. We may also consider entering into collaboration arrangements or selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to our stockholders. The incurrence of debt financing would result in debt service obligations and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations or our ability to incur additional indebtedness or pay dividends, among other items. If we raise additional funds through governmental funding,

22


 

collaborations, strategic partnerships and alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are not able to secure adequate additional funding, we may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially and adversely affect our business, financial condition, results of operations and prospects.

 

Cash Flows

The following table summarizes our cash flows for the period indicated (in thousands):

 

 

Six Months Ended
June 30,

 

 

 

2026
(Unaudited)

 

 

2025
(Unaudited)

 

Cash used in operating activities

 

$

(34,256

)

 

$

(36,568

)

Cash provided by (used in) investing activities

 

 

8,597

 

 

 

39,700

 

Cash provided by financing activities

 

 

143

 

 

 

113

 

Impact of exchange rates on cash and cash equivalents

 

 

2

 

 

 

6

 

Net increase (decrease) in cash and cash equivalents

 

$

(25,514

)

 

$

3,251

 

 

Operating Activities

Net cash used in operating activities for the six months ended June 30, 2026, was $34.3 million, which consisted primarily of net loss of $36.1 million, partially offset by non-cash charges of $2.2 million. Changes in our net operating assets and liabilities decreased operating cash by $0.4 million. The non-cash charges primarily consisted of stock-based compensation of $2.9 million, accretion of discounts on marketable securities of $0.8 million, and depreciation of $0.1 million. The change in our net operating assets and liabilities was primarily due to a decrease in accounts payable, partially offset by an increase in accrued expenses and a decrease in prepaid expenses and other assets.

Net cash used in operating activities for the six months ended June 30, 2025, was $36.6 million, which consisted primarily of net loss of $38.6 million partially offset by non-cash charges of $1.8 million. Changes in our net operating assets increased operating cash by $0.4 million. The non-cash charges primarily consisted of stock-based compensation of $3.2 million, accretion of discounts on marketable securities of $1.6 million, and depreciation of $0.1 million. The change in our net operating assets and liabilities was primarily due to an increase in prepaid expenses and other assets, and a decrease in outstanding payables and accrued expenses.

Investing Activities

Our investing activities provided $8.6 million of cash during the six months ended June 30, 2026, which consisted primarily of maturities of marketable securities of $46.0 million, partially offset by purchases of marketable securities of $37.4 million.

Our investing activities provided $39.7 million of cash during the six months ended June 30, 2025, which consisted primarily of maturities of marketable securities of $86.4 million, partially offset by purchases of marketable securities of $46.7 million.

Financing Activities

Our financing activities provided $0.1 million and $0.1 million of cash during the six months ended June 30, 2026 and 2025, respectively. This consisted of $0.1 million of proceeds from the purchase of common stock under our 2020 ESPP during the six months ended June 30, 2026 and $0.1 million of proceeds from the exercise of stock options for the six months ended June 30, 2025.

Critical Accounting Policies and Estimates

The preparation of our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and judgments that affect the amounts reported in those condensed consolidated financial statements and accompanying notes. Although we believe that the estimates we use are reasonable, due

23


 

to the inherent uncertainty involved in making those estimates, actual results reported in future periods could differ from those estimates.

We believe that the accounting policies described below involve a high degree of judgment and complexity. Accordingly, these are the policies we believe are the most critical to aid in fully understanding and evaluating our financial condition and results of our operations. During the six-month period ended June 30, 2026, there were no material changes to our critical accounting policies from those described in our audited consolidated financial statements for the year ended December 31, 2025, included in our Annual Report on Form 10-K filed with the SEC on March 6, 2026, except as noted below.

Research and Development Costs, Accrued Research and Development Costs and Related Prepaid Expenses

Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including sourcing of raw materials and manufacturing of our product candidates, allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development advance payments are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or services are performed.

As part of the process of preparing our condensed consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the condensed consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to:

•
vendors, including research laboratories, in connection with preclinical development activities;
•
CROs and investigative sites in connection with preclinical studies and clinical trials; and
•
CMOs in connection with drug substance and drug product formulation of preclinical studies and clinical trial materials.

We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions and CROs that supply, conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.

Recent Accounting Pronouncements

For a description of recent accounting pronouncements, see Note 2 of the notes to our unaudited condensed consolidated financial statements for the six months ended June 30, 2026 included elsewhere in this Quarterly Report on Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rate risks.

We had cash, cash equivalents, and marketable securities of $79.4 million as of June 30, 2026. The Company’s cash equivalents consist of interest-bearing U.S. government securities, money market funds, and corporate debt securities. Our exposure due to changes in interest rates is not material due to the nature and amount of our money-market funds and marketable securities.

24


 

We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we may contract with foreign vendors that are located outside the United States in the future. This may subject us to fluctuations in foreign currency exchange rates in the future.

Item 4. Controls and Procedures.

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Securities Exchange Act of 1934, as amended, reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

We carry out a variety of ongoing procedures, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, to evaluate the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026.

There have not been any changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

25


 

PART II—OTHER INFORMATION

We are not currently involved in any litigation or legal proceedings that, in management’s opinion, are likely to have any material adverse effect on the Company.

Item 1A. Risk Factors.

Other than as described below, there have been no material changes to the Company’s risk factors as set forth in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC on March 6, 2026, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as filed with the SEC on May 12, 2026, which are hereby incorporated by reference. You should carefully review and consider the information regarding such risk factors and the risks and uncertainties described elsewhere in this report which could materially affect our business, financial condition or future prospects.

There is substantial doubt as to our ability to continue as a going concern. We may need additional financing to execute our business plan, to fund our operations, and to continue as a going concern. Our disclosure regarding the substantial doubt as to our ability to continue as a going concern may hinder our ability to obtain further financing.

Due to our recurring operating losses and negative cash flows from operations and our dependence on and uncertainty around our ability to obtain additional financing to fund our operations after our current resources are exhausted, management has determined that our present capital resources may not be sufficient to fund our planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to our ability to continue as a going concern. Our ability to continue as a going concern will depend on our ability to obtain additional funding, which may divert management’s attention, and no assurances can be given that additional funding will be available to us on commercially reasonable terms, or at all. If we are unable to raise sufficient capital when needed, our business, financial condition and results of operations will be materially adversely affected, and we will need to modify our operational plans to continue as a going concern. If we are unable to obtain sufficient financing, we may be required to delay, reduce the scope of, or cease some or all of our research and development programs, or pursue strategic alternatives. Moreover, the reaction of investors to the inclusion of a going concern statement in our financial statements and our potential inability to continue as a going concern could adversely affect the price of our common stock and our ability to raise new capital or enter into collaborative or other transactions.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

(a) Unregistered Sales of Equity Securities

None.

(b) Use of Proceeds

Our initial public offering of our common stock was effected pursuant to a registration statement on Form S-1 (File No. 333-248627), which was declared effective by the SEC on September 24, 2020. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on September 24, 2020.

(c) Issuer Purchases of Equity Securities.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

Rule 10b5-1 Trading Arrangements

26


 

During the three months ended June 30, 2026, none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

27


 

Item 6. Exhibits.

 

Exhibit

Number

 

Description

Form

File No.

Number

Filing Date

 

 

 

 

 

 

 

3.1

 

Amended and Restated Certificate of Incorporation of the Registrant.

8-K

001-39539

3.1

September 29, 2020

 

 

 

 

 

 

 

3.2

 

Amended and Restated Bylaws of the Registrant.

10-Q

001-39539

3.3

May 10, 2023

 

 

 

 

 

 

 

31.1+

 

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

31.2+

 

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

32.1+†

 

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

32.2+†

 

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

101.INS

Inline XBRL Instance Document.

 

 

 

 

 

 

 

 

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document.

 

 

 

 

 

 

 

 

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

 

 

 

 

 

† The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

+ Filed herewith.

28


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

PMV Pharmaceuticals, Inc.

Date: August 14, 2026

By:

/s/ David H. Mack

David H. Mack, Ph.D.

President, Chief Executive Officer, and Director

 

 

 

(Principal Executive Officer)

 

 

 

 

 

 

PMV Pharmaceuticals, Inc.

 

Date: August 14, 2026

By:

/s/ Michael Carulli

Michael Carulli

Chief Financial Officer

 

 

 

(Principal Financial and Accounting Officer)

 

29


EX-31.1 2 pmvp-ex31_1.htm EX-31.1 EX-31.1

 

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David H. Mack, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2026, of PMV Pharmaceuticals, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: August 14, 2026

By:

/s/ David H. Mack

David H. Mack, Ph.D.

President, Chief Executive Officer,

and Director

(Principal Executive Officer)

 

 


EX-31.2 3 pmvp-ex31_2.htm EX-31.2 EX-31.2

 

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael Carulli, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2026, of PMV Pharmaceuticals, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: August 14, 2026

By:

/s/ Michael Carulli

Michael Carulli

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 


EX-32.1 4 pmvp-ex32_1.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the period ended June 30, 2026, of PMV Pharmaceuticals, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 14, 2026

By:

/s/ David H. Mack

David H. Mack, Ph.D.

President, Chief Executive Officer, and Director

(Principal Executive Officer)

 

 


EX-32.2 5 pmvp-ex32_2.htm EX-32.2 EX-32.2

 

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the period ended June 30, 2026, of PMV Pharmaceuticals, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 14, 2026

By:

/s/ Michael Carulli

Michael Carulli

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 


EX-101.SCH 6 pmvp-20260630.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 75000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 75010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Formation and Business of the Company link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Stock Plan link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Related Parties link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Stock Plan (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Formation and Business of the Company - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Fair Value Measurements - Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Property and Equipment, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Commitments and Contingencies - Additional Information (Details) [Default] link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Commitments and Contingencies - Summary of Components of Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Commitments and Contingencies - Schedule of Amounts Reported in Consolidated Balance Sheets for Leases (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Commitments and Contingencies - Summary of Other Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details) 2 link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Stock Plan - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Stock Plan - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Stock Plan - Schedule of Estimated Fair Value of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Stock Plan - Summary of Weighted Average Assumptions Used to Estimate Fair value of Stock Purchase Rights Under ESPP (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Stock Plan - Schedule of RSU Activity Under the 2020 Plan (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Stock Plan - Stock-based Compensation Expense Related to Options Granted and Common Stock Issued under 2020 ESPP Recorded and Allocated (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Stock Plan - Stock-based Compensation Expense Related to Options Granted and Common Stock Issued under 2020 ESPP Recorded and Allocated (Details) [Default] link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Stock Plan - Schedule of Stock-based Compensation Expense by Award Type (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Net Loss per Share - Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Related Parties - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Restructuring - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Segment Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Segment Information - Summary of Significant Segment Expenses Regularly Provided to the CEO (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Segment Information - Summary of Significant Segment Expenses Regularly Provided to the CEO (Details) [Default] link:presentationLink link:calculationLink link:definitionLink Related Party Transaction [Table] Schedule Of Related Party Transactions By Related Party [Table] Proceeds from Sale and Maturity of Marketable Securities Maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities, Total Restructuring and Related Activities Disclosure [Text Block] Restructuring Common Stock, Capital Shares Reserved for Future Issuance Number of shares reserved for issuance Schedule of Accrued Liabilities [Table Text Block] Summary of Accrued Expenses Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total Operating Lease, Liability Total operating lease liabilities Present value of lease liabilities Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized compensation cost Long-Term Line of Credit, Total Long-Term Line of Credit Letter of credit Commitments and Contingencies Commitments and contingencies (see Note 6) Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Weighted-average common shares outstanding - diluted Weighted-average number of shares - diluted APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Minimum [Member] Minimum Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Segment Reporting [Line Items] Reimbursements received from lessee1. Reimbursements Received From Lessee1 Reimbursements received from lessor Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total Benefit for income taxes Provision (benefit) for income taxes Exercise of Stock Options and Common Stock Issued Under Employee Stock Purchase Plan and Release of Vested Restricted Stock Units Value Exercise of stock options and common stock issued under employee stock purchase plan and release of vested restricted stock units value. Exercise of stock options, common stock issued under the 2020 ESPP, and release of vested restricted stock units Related Party Transaction [Line Items] Related Party Transaction [Line Items] Unvested RSUs Restricted Stock Units (RSUs) [Member] Restricted stock units ESPP Employee Stock Purchase Plan [Member] Employee stock purchase plan. Employee stock purchase plan Operating Segments [Member] Operating Segments [Member] Lessee Operating Lease Liability To Be Paid Net Of Repayments After Year Three Lessee operating lease liability payments, net of reimbursements, due year three. Thereafter Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation [Abstract] Cash and cash equivalents Debt Securities, Available-for-Sale, Amortized Cost Carrying Amount Share-based compensation arrangement by share-based payment award, number of shares available for grant, forfeitures in period. Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period Shares Available for Grant, Options forfeited / cancelled Lessee operating lease liability payments, net of reimbursements, due next twelve months. Lessee Operating Lease Liability Payments Net Of Reimbursements Due Next Twelve Months 2027 Share based compensation arrangement by share based payment award, number of shares available for grant, exercised in period. Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised In Period Shares Available for Grant, Options exercised Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Amounts representing imputed interest Property, Plant, and Equipment [Text Block] Property and Equipment, Net Restricted Cash, Current Restricted cash Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised, Total Proceeds from the exercise of stock options and common stock issued under the 2020 Plan Schedule of lease amount reported in balance sheet. Schedule Of Lease Amount Reported In Balance Sheet Table [Text Block] Schedule of Amounts Reported in Consolidated Balance Sheets for Leases General and Administrative Expense Total general and administrative Total general and administrative Income Statement [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of Stock Units, Forfeited Lease, Cost [Table Text Block] Summary of Components of Lease Cost Related and Nonrelated Parties [Domain] Related Party Earnings Per Share, Basic, Total Earnings Per Share, Basic Net loss per share - basic Lessee operating lease liability payments, net of reimbursements, due year three. Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Three 2029 Document Period End Date Document Period End Date Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment, Total Purchases of property and equipment Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options granted, Weighted Average Exercise Price Granted options at an exercise price Common Stock, Shares Authorized Common stock, shares authorized Statement of Stockholders' Equity [Abstract] Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Share-based compensation arrangement by share-based payment award, number of shares available for grant, shares reserved for issuance. Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Reserved For Issuance Shares Available for Grant, Shares reserved for issuance Sharebased compensation arrangement by sharebased payment award options exercised weighted average remaining contractual term. Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised Weighted Average Remaining Contractual Term Options Forfeited/Cancelled, Weighted-Average Remaining Contractual Life Other Comprehensive Income (Loss), Net of Tax Total other comprehensive loss Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Options Outstanding, Aggregate Intrinsic Value Assets Total assets Area of Land Lease area of square feet Title of 12(b) Security Title of 12(b) Security Preferred Stock, Value, Issued Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Preferred stock, $0.00001 par value, 5,000,000 shares authorized at June 30, 2026 and December 31, 2025. No shares issued or outstanding at June 30, 2026 and December 31, 2025. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of Stock Units, Beginning balance Number of Stock Units, Ending balance Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of Stock-based Compensation Expense by Award Type Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Options granted, Number of Options Options awarded Operating Lease, Payments Operating lease, payments Cash payment Antidilutive Securities, Name [Domain] Research Research Research Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Share based compensation arrangement by share based payment award options weighted-average remaining life. Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Life [Abstract] Weighted-Average Remaining Contractual Life Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted-Average Remaining Contractual Term Options Outstanding, Weighted-Average Remaining Contractual Life Segment Reporting [Table Text Block] Summary of Significant Segment Expenses Regularly Provided to the CEO Two thousand twenty employee stock purchase plan. Two Thousand Twenty Employee Stock Purchase Plan [Member] 2020 ESPP Hopewell New Jersey [Member] Hopewell, New Jersey. Hopewell, New Jersey Equity, Attributable to Parent Balance Balance Total stockholders’ equity Operating Leases: Assets and Liabilities, Lessee [Abstract] Entity Address, Address Line Two Entity Address, Address Line Two Other Assets, Noncurrent Other assets Other Assets, Noncurrent, Total Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Income Tax Disclosure [Text Block] Income Taxes Lessee operating lease liability payments, net of repayments, due. Lessee Operating Lease Liability Payments Net Of Repayments Due Total minimum lease payments Earnings Per Share [Text Block] Net Loss per Share Loss on termination of lease, net Gain (Loss) on Termination of Lease Gain on termination of lease, net Number of reportable segment Number of Reportable Segments Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Concentration of credit risk and other risks and uncertainties. Concentration Of Credit Risk And Other Risks And Uncertainties Policy [Text Block] Concentration of Credit Risk and Other Risks and Uncertainties External General and Administrative Expenses External general and administrative expenses. External Net Gain Loss from Lease Termination Agreement Net gain loss from lease termination agreement. Net gain (loss) from lease termination agreement Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Termination fee Termination fee Termination fee Short-term lease cost Short-Term Lease, Cost Geographical [Domain] Geographical Expected cash received from sale of unsued net operating loss carryforwards and R&D tax credits. Expected Cash Received from Sale of Unsued Net Operating Loss Carryforwards and R&D Tax Credits Expected cash received from sale of unsued NOL carryforwards and R&D tax credits Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Statistical Measurement [Axis] Statistical Measurement Money Market Funds [Member] Money Market Funds Entity Interactive Data Current Entity Interactive Data Current Expected volatility, Maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Stock-based Compensation Expense Related to Options Granted and Common Stock Issued under 2020 ESPP Recorded and Allocated Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Vested , Weighted-Average Remaining Contractual Life Common Stock, Value, Issued Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Common stock, $0.00001 par value, 1,000,000,000 shares authorized; 53,460,432 and 53,331,766 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively. US Government Agencies Debt Securities [Member] Government Securities Government Debt Securities Business Description and Basis of Presentation [Text Block] Formation and Business of the Company Property and Equipment Property, Plant, and Equipment [Policy Text Block] Proceeds from Sale of Property, Plant, and Equipment Proceeds from Sale of Property, Plant, and Equipment, Total Proceeds from sale of property and equipment Liabilities Total liabilities Schedule of other information related to leases. Schedule Of Other Information Related To Leases Table [Text Block] Summary of Other Information Related to Leases Other, net Other Other Noncash Income (Expense) Other Noncash Income (Expense), Total Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Entity Bankruptcy Proceedings, Reporting Current Entity Bankruptcy Proceedings, Reporting Current Fair Value, Inputs, Level 3 [Member] Significant Unobservable Inputs (Level 3) Level 3 Other Nonoperating Income (Expense) [Abstract] Other income (expense): Gain (Loss) on Disposition of Property Plant Equipment Gain (Loss) on Disposition of Property Plant Equipment, Total Loss on sales and disposals of fixed assets, net Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Total Operating Expenses Total operating expenses Share based compensation arrangement by share based payment award number of shares available for grant restricted stock units grants in period. Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Restricted Stock Units Grants in Period Shares Available for Grant, RSU's granted Share-based compensation arrangement by share-based payment award, annual increase of authorized shares, percent of common stock outstanding. Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Of Authorized Shares Percent Of Common Stock Outstanding Percentage of number of shares of common stock outstanding increase Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Change in operating assets and liabilities: Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period on an annual basis Common stock shares sold Issuance of common stock, net of issuance costs , Shares Stock Issued During Period, Shares, New Issues Net Operating Loss and R&D Tax Credit Sale [Member] Net operating loss and r&d tax credit sale. Net Operating Loss and R&D Tax Credit Sale Restricted Cash Restricted cash Restricted Cash, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, Maximum Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Consulting fees Operating Costs and Expenses Operating Costs and Expenses, Total Related Party Transactions [Abstract] Operating Lease, Cost Operating lease cost Income tax paid net refund received Income Tax Paid Net Refunds Received Income Tax Paid Net Refunds Received Long-Lived Asset, Class [Axis] Long-Lived Tangible Asset Subsequent Events [Text Block] Subsequent Event Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Impact of exchange rates on cash, cash equivalents, and restricted cash Impact of exchange rates on cash and cash equivalents Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Property, Plant, and Equipment [Line Items] Property Plant And Equipment [Line Items] Money Market Funds, Corporate Securities and Government Securities [Member] Money market funds, corporate securities and government securities. Money Market Funds, Corporate Securities and Government Securities Corporate Debt Securities [Member] Corporate Securities Corporate Debt Securities Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Labor and Related Expense Personnel related Debt Securities, Available-for-Sale Fair Value Debt Securities, Available-for-sale, Total Board of directors. Board Of Directors [Member] Board of Directors Operating Lease, Liability, Current Operating lease liability, current Operating lease liabilities, current Option Indexed to Issuer's Equity, Type [Domain] Lessee operating lease liability payments, net of reimbursements, due year two. Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Two 2028 Lessee, Operating Lease, Existence of Option to Extend [true false] Weighted-Average Grant Date Fair Value, Beginning balance Weighted-Average Grant Date Fair Value, Beginning balance Weighted-Average Grant Date Fair Value, Ending balance Total liabilities and stockholders’ equity Liabilities and Equity Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Total research and development Research and Development Expense Total research and development Document Fiscal Period Focus Document Fiscal Period Focus Tax Credit Carryforward [Axis] Assets not placed in service. Assets Not Placed In Service [Member] Assets Not Placed in Service Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Estimated Fair Value of Stock Options Commitments and contingencies disclosure. Commitments And Contingencies Disclosure [Line Items] Commitments And Contingencies Disclosure [Line Items] Property, Plant, and Equipment [Table] Schedule Of Property Plant And Equipment [Table] Sale of Stock [Axis] Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Net (decrease) increase in cash and cash equivalents Entity Current Reporting Status Entity Current Reporting Status Common stock, capital shares reserved for future issuance, additional shares reserved, minimum. Common Stock Capital Shares Reserved For Future Issuance Additional Shares Reserved Minimum Number of additional shares reserved for issuance, minimum Use of Estimates, Policy [Policy Text Block] Use of Estimates Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Exercisable, Number of Options Level 1 Fair Value, Inputs, Level 1 [Member] Quoted Priced in Active Markets (Level 1) Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share Financial Instrument [Axis] Financial Instrument Assets, Fair Value Disclosure Total financial assets Assets, Fair Value Disclosure, Total Document Transition Report Document Transition Report Other Non Cash Lease Income Expense Other non cash lease (income) expense. Non-cash lease income Commitments and Contingencies Disclosure [Abstract] Accounting Standards Update [Domain] Liabilities, Current [Abstract] Current liabilities: Share-Based Payment Arrangement [Abstract] Common Stock [Member] Common Stock Cash, cash equivalents and marketable securities. Cash Cash Equivalents And Marketable Securities Policy [Text Block] Cash, Cash Equivalents, and Marketable Securities Accounting Standards Update [Axis] Statistical Measurement [Domain] Statistical Measurement Marketable Securities Marketable Securities, Total Employee Severance [Member] Employee Severance and Benefit Costs Employee severance and benefit costs Equity, Attributable to Parent [Abstract] Stockholders’ equity: Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Weighted-average common shares outstanding - basic Weighted-average number of shares - basic Property, Plant, and Equipment [Abstract] Assets [Abstract] Assets Operating Lease, Expense Rent expense Entity Central Index Key Entity Central Index Key Restructuring Charges, Total Restructuring Charges Restructuring charges Expenses, net Antidilutive Securities [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Exercisable, Aggregate Intrinsic Value Consolidation Items [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Accrued Liabilities, Total Document Quarterly Report Document Quarterly Report Aggregate gross sales proceeds Aggregate Gross Sales Proceeds Under Sales Agreement Aggregate gross sales proceeds under sales agreement. Cash and Cash Equivalents [Axis] Cash and Cash Equivalents Lease Expiration Date Lease expiring date Money Market Funds and Government Securities Money Market Funds and Government Securities [Member] Money Market Funds and Government Securities. Fair Value, Inputs, Level 2 [Member] Significant Other Observable Inputs (Level 2) Level 2 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options Outstanding, Weighted Average Exercise Price Options Outstanding, Weighted Average Exercise Price Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Net cash used in operating activities Cash used in operating activities Cash used in operating activities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Net loss per share - diluted Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Shares issued Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate Net loss Net loss Net loss Option Indexed to Issuer's Equity, Type [Axis] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Long-Lived Asset, Class [Domain] Long-Lived Tangible Asset Write off of lease hold improvements Write Off of Lease Hold Improvements Write off of lease hold improvements. Cash, Cash Equivalents, and Short-Term Investments Cash, cash equivalents, and marketable securities Cash, Cash Equivalents, and Short-term Investments, Total Type of Restructuring [Domain] Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive loss Option Exchange [Member] Option exchange. Option Exchange Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation gain (loss) Equity Components [Axis] Accumulated Other Comprehensive Loss Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Cash flows from investing activities: Statement of Cash Flows [Abstract] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Income Tax Disclosure [Abstract] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options exercised, Weighted Average Exercise Price Development Development Expense Development expense. Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Fair Value Disclosures [Text Block] Fair Value Measurements ASU 2023-09 Accounting Standards Update 2023-09 [Member] Machinery and Equipment [Member] Machinery & Equipment Preferred Stock, Shares Authorized Preferred stock, shares authorized OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized loss on investments Antidilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Share-based compensation arrangement by share-based payment award, number of shares available for grant, grants in period. Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Grants In Period Shares Available for Grant, Options granted Number of Operating Segments Number of operating segment AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss Accumulated Other Comprehensive (Loss) Income Shares available for future stock option and RSU grants Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Shares Available for Grant, Balance Shares Available for Grant, Balance Aggregrate Shares Expected shares to be purchased under 2020 ESPP Expected Shares to be Purchased under Two Thousand Twenty ESPP [Member] Expected shares to be purchased under two thousand twenty ESPP. Michael Carulli [Member] Michael Carulli. Michael Carulli Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Options forfeited / cancelled, Weighted Average Exercise Price Lessee, Operating Lease, Description Operating lease, description Accrued Liabilities, Current Accrued expenses Total Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Summary of significant accounting policies. Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Options Outstanding, Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Options Outstanding, Number of Options Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values BMR-One Research Way LLC. BMR-One Research Way LLC [Member] BMR-One Research Way LLC Dividends, Common Stock Dividends, common stock declared Dividends, Common Stock, Total Document Type Document Type Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Cash flows from operating activities: Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Liabilities and Equity [Abstract] Liabilities and Stockholders’ Equity Operating Income (Loss) Loss from operations Loss from Operations Segment Reporting [Table] Income Tax Contingency [Line Items] Asset Class [Domain] Asset Class Securities Act File Number Entity File Number Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Workers' Compensation Liability, Current Accrued compensation Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases Location, Statement of Income, Balance [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, Minimum Retained Earnings [Member] Accumulated Deficit Exercise of stock options and common stock issued under employee stock purchase plans. Exercise Of Stock Options And Common Stock Issued Under Employee Stock Purchase Plans Exercise of stock options and common stock issued under the 2020 ESPP, Shares Entity Registrant Name Entity Registrant Name Accounting Policies [Abstract] Depreciation Depreciation Depreciation, Total Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Exercise of Stock Options and Common Stock Issued Under Employee Stock Purchase Plan and Release of Vested Restricted Stock Units Shares Exercise of stock options and common stock issued under employee stock purchase plan and release of vested restricted stock units shares. Exercise of stock options, common stock issued under the 2020 ESPP, and release of vested restricted stock units, Shares Entity Address, Address Line One Entity Address, Address Line One Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses Subsidiary, Sale of Stock [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercise of stock options, Shares Options exercised, Number of Options Restructuring Cost [Table] Schedule of Restructuring and Related Costs [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable, Weighted Average Exercise Price Assets, Current Total current assets Furniture and Fixtures [Member] Furniture & Fixtures Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Commitments and contingencies disclosure. Commitments And Contingencies Disclosure [Table] Commitments And Contingencies Disclosure [Table] Related Party Transactions Disclosure [Text Block] Related Parties Entity Small Business Entity Small Business Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total compensation cost related to nonvested awards not yet recognized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Issuance. Available for Issuance Interest Income (Expense), Operating Interest income, net Interest Income (Expense), Net, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Forfeited Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Lease Termination Agreement Lease Termination Agreement. Lease Termination Agreement [Member] Accrued research and development costs current. Accrued Research And Development Costs Current Accrued research and development costs Consolidation Items [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Restructuring and Related Activities [Abstract] Earnings Per Share [Abstract] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Stock Option Activity Plan Name Plan Name [Axis] Equity [Abstract] Equity [Text Block] Stockholders' Equity Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Cash flows from financing activities: Operating leases, extended year. Operating Leases Extended Year Operating Leases, extended year Shares outstanding Share Based Compensation Arrangement By Share Based Payment Award Shares Outstanding Number Share-based compensation arrangement by share-based payment award, shares outstanding, number. Marketable securities, noncurrent Marketable Securities, Noncurrent Marketable Securities, Noncurrent, Total Other nonoperating income (expense), other. Other Nonoperating Income Expense Other Other income (expense), net Entity Tax Identification Number Entity Tax Identification Number Equity Component [Domain] Equity Component Entity Address, City or Town Entity Address, City or Town Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Operating leases extended month and year. Operating Leases Extended Month And Year Operating leases extended month and year Common stock, capital shares reserved for future issuance, additional shares reserved, maximum. Common Stock Capital Shares Reserved For Future Issuance Additional Shares Reserved Maximum Number of additional shares reserved for issuance, maximum Gross proceeds available for future issuances of common stock Common Stock Available For Future Issuance Common stock available for future issuance. Segment Reporting, Expense Information Used by CODM, Description Antidilutive Security, Excluded EPS Calculation [Table] Net Cash Paid (Received) For Amounts Included In The Measurement Of Lease Liabilities Net cash paid (received) for amounts included in the measurement of lease liabilities. Net cash paid for amounts included in the measurement of lease liabilities Payments to Acquire Marketable Securities Payments to Acquire Marketable Securities, Total Purchases of marketable securities Statement [Table] Statement [Table] Lease, Cost Total lease cost Share-Based Payment Arrangement, Expense Total stock-based compensation Stock-based compensation Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before (benefit) for income taxes Entity Shell Company Entity Shell Company Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected life (in years) Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Net cash provided by investing activities Statement [Line Items] Statement [Line Items] Tax Credit Carryforward, Name [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Number of Stock Units, Vested Number of Stock Units, Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Maximum [Member] Maximum Sale of Stock [Domain] OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total Unrealized (loss) on available for sale investments, net of tax Two thousand twenty equity incentive plan. Two Thousand Twenty Equity Incentive Plan [Member] 2020 Plan Lease Commencement Date Lease commencement date. Lease commencement date Exercise of stock options and common stock value issued under employee stock purchase plans. Exercise Of Stock Options And Common Stock Value Issued Under Employee Stock Purchase Plans Exercise of stock options and common stock issued under the 2020 ESPP Right Of Use Asset Obtained (Derecognized) in Exchange for Operating Lease Liability Right of use asset obtained (derecognized) in exchange for operating lease liability. Leased assets obtained in exchange for new or modified operating lease liabilities Effective Tax Rates Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Open Tax Year Subsequent Events [Abstract] Asset Class [Axis] Asset Class Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Granted Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Restructuring Cost and Reserve [Line Items] Assets, Current [Abstract] Current assets: Accrued Professional Fees, Current Accrued legal and professional services Leases [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Accretion (Amortization) of Discounts and Premiums, Investments Accretion of discounts on marketable securities Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Restructuring Type [Axis] Options to purchase common stock. Options to Purchase Common Stock [Member] Options to purchase common stock Financial Instruments [Domain] Financial Instruments Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Vested, Aggregate Intrinsic Value Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Operating lease liabilities, noncurrent Operating Lease, Liability, Noncurrent Operating lease liabilities, non-current Debt Securities, Available-for-Sale, Allowance for Credit Loss Allowance for credit losses Debt Securities, Available-for-sale, Allowance for Credit Loss, Total Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance Increase (decrease) in operating lease right-of-use assets and liabilities. Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Operating lease right-of-use assets and liabilities Payments for (Proceeds from) Tenant Allowance Tenant improvement allowance Other Accrued Liabilities, Current Other accrued liabilities Additional Paid in Capital, Common Stock, Ending Balance Additional Paid in Capital, Common Stock Additional paid-in capital Additional Paid in Capital, Common Stock, Beginning Balance Security Exchange Name Security Exchange Name Related and Nonrelated Parties [Axis] Related Party New Accounting Pronouncements, Policy [Policy Text Block] Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted Princeton, New Jersey. Princeton New Jersey [Member] Princeton, New Jersey Entity Address, State or Province Entity Address, State or Province Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unrecognized compensation cost, weighted average period of recognition Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, Minimum Number of consulting agreements members. Number Of Consulting Agreements Members Number of consulting agreement members Right-of-use assets, operating leases Right-of-use assets Operating Lease, Right-of-Use Asset Amendment Flag Amendment Flag Share-Based Payment Arrangement [Text Block] Stock Plan Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Other Nonoperating Income (Expense) Total other income Operating lease terminated period. Operating Lease Terminated Period Terminated period City Area Code City Area Code Share based compensation arrangement by share based payment award options shares available for grant. Share Based Compensation Arrangement By Share Based Payment Award Options Shares Available For Grant Roll Forward Shares Available For Grant Organization, Consolidation and Presentation of Financial Statements [Abstract] Comprehensive Income, Policy [Policy Text Block] Comprehensive Loss and Accumulated Other Comprehensive Income (Loss) Leaseholds and Leasehold Improvements [Member] Leasehold Improvements Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Operating Expenses [Abstract] Operating expenses: Computer Equipment [Member] Computers Operating Leases, extension period Operating Leases Extension Period Operating leases, extension period Amount owed to related party Other Liabilities Other Liabilities, Total Common Stock, Par or Stated Value Per Share Common stock, par value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted-Average Remaining Contractual Term Exercisable, Weighted-Average Remaining Contractual Life Lessee, Leases [Policy Text Block] Leases Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Vested , Number of Options Liabilities, Current Total current liabilities Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization Total property and equipment Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Cash and cash equivalents - beginning of period Cash and cash equivalents - end of period Variable Lease, Cost Variable lease cost Segment Information Segment Reporting [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Trading Symbol Trading Symbol Geographical [Axis] Geographical Property, Plant, and Equipment [Table Text Block] Summary of Property and Equipment, Net Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Number of Stock Units, Granted Restricted stock units granted to employees Entity Emerging Growth Company Entity Emerging Growth Company Additional Paid-in Capital [Member] Additional Paid-in Capital Plan Name [Domain] Plan Name ATM Program At The Market Equity Offering Program [Member] At the market equity offering program. Lessee operating lease liability payments, net of reimbursements, remainder of fiscal year. Lessee Operating Lease Liability Payments Net Of Reimbursements Remainder Of Fiscal Year 2026 Leasehold Improvements, Gross Leasehold improvements Cover [Abstract] Termination effective date Termination effective date Termination effective date Income Tax Contingency [Table] Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term (years) Schedule of RSU Activity Under the 2020 Plan Nonvested Restricted Stock Shares Activity [Table Text Block] Schedule of RSU Activity Under the 2020 Plan Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Debt Securities, Available-for-sale, Unrealized Gain (Loss), Total Accretion of available-for-sale debt securities Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive income (loss) Property, Plant, and Equipment, Useful Life Property and equipment, Estimated useful lives Sublease Agreement [Member] Sublease agreement. Sublease Agreement Share-Based Payment Arrangement, Noncash Expense Share-based Payment Arrangement, Noncash Expense, Total Stock-based compensation expense Share based compensation arrangement by share based payment award options intrinsic value. Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract] Aggregate Intrinsic Value Fair Value Disclosures [Abstract] Cash and Cash Equivalent Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash equivalent Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Net cash provided by financing activities Payables and Accruals [Abstract] Cash Equivalents, at Carrying Value Cash equivalents Cash Equivalents, at Carrying Value, Total Aggregate cash and cash equivalents Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Options forfeited / cancelled, Number of Options Entity Filer Category Entity Filer Category Marketable securities, current Marketable Securities, Current Marketable Securities, Current, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested , Weighted Average Exercise Price Restructuring and related cost, number of positions eliminated, period percent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Shares, Outstanding Balance, Shares Balance, Shares Segment Reporting [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Statement of Financial Position [Abstract] Local Phone Number Local Phone Number XML 8 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2026
Aug. 14, 2026
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2026  
Entity File Number 001-39539  
Entity Registrant Name PMV PHARMACEUTICALS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 46-3218129  
Entity Address, Address Line One 400 Alexander Park Drive  
Entity Address, Address Line Two Suite 301  
Entity Address, City or Town Princeton  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 08540  
City Area Code 609  
Local Phone Number 642-6670  
Title of 12(b) Security Common stock, par value $0.00001  
Trading Symbol PMVP  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   53,458,058
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2026  
Document Fiscal Period Focus Q2  
Entity Central Index Key 0001699382  
Amendment Flag false  
XML 9 R2.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 12,469 $ 37,983
Marketable securities, current 66,962 74,960
Prepaid expenses and other current assets 1,978 2,284
Total current assets 81,409 115,227
Property and equipment, net 154 237
Right-of-use assets 209 801
Other assets 296 297
Total assets 82,068 116,562
Current liabilities:    
Accounts payable 2,020 3,155
Accrued expenses 8,331 7,857
Operating lease liabilities, current 217 403
Total current liabilities 10,568 11,415
Operating lease liabilities, noncurrent 0 435
Total liabilities 10,568 11,850
Commitments and contingencies (see Note 6)
Stockholders’ equity:    
Preferred stock, $0.00001 par value, 5,000,000 shares authorized at June 30, 2026 and December 31, 2025. No shares issued or outstanding at June 30, 2026 and December 31, 2025.
Common stock, $0.00001 par value, 1,000,000,000 shares authorized; 53,460,432 and 53,331,766 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively.
Additional paid-in capital 554,160 551,082
Accumulated deficit (482,578) (446,454)
Accumulated other comprehensive income (loss) (82) 84
Total stockholders’ equity 71,500 104,712
Total liabilities and stockholders’ equity $ 82,068 $ 116,562
XML 10 R3.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Jun. 30, 2026
Dec. 31, 2025
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.00001 $ 0.00001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.00001 $ 0.00001
Common stock, shares authorized 1,000,000,000 1,000,000,000
Common stock, shares issued 53,460,432 53,331,766
Common stock, shares outstanding 53,460,432 53,331,766
XML 11 R4.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Operating expenses:        
Total research and development $ 14,676 $ 18,400 $ 30,006 $ 35,841
Total general and administrative 4,205 4,479 7,894 8,600
Total operating expenses 18,881 22,879 37,900 44,441
Loss from operations (18,881) (22,879) (37,900) (44,441)
Other income (expense):        
Interest income, net 788 1,690 1,768 3,625
Other income (expense), net 10 (16) 11 (21)
Total other income 798 1,674 1,779 3,604
Loss before (benefit) for income taxes (18,083) (21,205) (36,121) (40,837)
Provision (benefit) for income taxes 3 5 3 (2,191)
Net loss (18,086) (21,210) (36,124) (38,646)
Unrealized (loss) on available for sale investments, net of tax (67) (61) (168) (123)
Foreign currency translation gain (loss) 0 (2) 2 6
Total other comprehensive loss (67) (63) (166) (117)
Total comprehensive loss $ (18,153) $ (21,273) $ (36,290) $ (38,763)
Net loss per share - basic $ (0.34) $ (0.41) $ (0.68) $ (0.74)
Net loss per share - diluted $ (0.34) $ (0.41) $ (0.68) $ (0.74)
Weighted-average common shares outstanding - basic 53,386,909 52,010,827 53,359,490 51,981,607
Weighted-average common shares outstanding - diluted 53,386,909 52,010,827 53,359,490 51,981,607
XML 12 R5.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Balance at Dec. 31, 2024 $ 176,080   $ 544,653 $ 139 $ (368,712)
Balance, Shares at Dec. 31, 2024   51,935,134      
Exercise of stock options 10   10    
Exercise of stock options, Shares   19,001      
Stock-based compensation expense 1,508   1,508    
Net loss (17,436)       (17,436)
Unrealized loss on investments (62)     (62)  
Foreign currency translation gain (loss) 7     7  
Balance at Mar. 31, 2025 160,107   546,171 84 (386,148)
Balance, Shares at Mar. 31, 2025   51,954,135      
Balance at Dec. 31, 2024 176,080   544,653 139 (368,712)
Balance, Shares at Dec. 31, 2024   51,935,134      
Net loss (38,646)        
Foreign currency translation gain (loss) 6        
Balance at Jun. 30, 2025 140,605   547,942 21 (407,358)
Balance, Shares at Jun. 30, 2025   52,993,238      
Balance at Mar. 31, 2025 160,107   546,171 84 (386,148)
Balance, Shares at Mar. 31, 2025   51,954,135      
Exercise of stock options, common stock issued under the 2020 ESPP, and release of vested restricted stock units 103   103    
Exercise of stock options, common stock issued under the 2020 ESPP, and release of vested restricted stock units, Shares   1,039,103      
Stock-based compensation expense 1,668   1,668    
Net loss (21,210)       (21,210)
Unrealized loss on investments (61)     (61)  
Foreign currency translation gain (loss) (2)     (2)  
Balance at Jun. 30, 2025 140,605   547,942 21 (407,358)
Balance, Shares at Jun. 30, 2025   52,993,238      
Balance at Dec. 31, 2025 104,712   551,082 84 (446,454)
Balance, Shares at Dec. 31, 2025   53,331,766      
Stock-based compensation expense 1,392   1,392    
Net loss (18,038)       (18,038)
Unrealized loss on investments (101)     (101)  
Foreign currency translation gain (loss) 2     2  
Balance at Mar. 31, 2026 87,967   552,474 (15) (464,492)
Balance, Shares at Mar. 31, 2026   53,331,766      
Balance at Dec. 31, 2025 $ 104,712   551,082 84 (446,454)
Balance, Shares at Dec. 31, 2025   53,331,766      
Exercise of stock options, Shares 0        
Net loss $ (36,124)        
Foreign currency translation gain (loss) 2        
Balance at Jun. 30, 2026 71,500   554,160 (82) (482,578)
Balance, Shares at Jun. 30, 2026   53,460,432      
Balance at Mar. 31, 2026 87,967   552,474 (15) (464,492)
Balance, Shares at Mar. 31, 2026   53,331,766      
Exercise of stock options, common stock issued under the 2020 ESPP, and release of vested restricted stock units 143   143    
Exercise of stock options, common stock issued under the 2020 ESPP, and release of vested restricted stock units, Shares   128,666      
Stock-based compensation expense 1,543   1,543    
Net loss (18,086)       (18,086)
Unrealized loss on investments (67)     (67)  
Foreign currency translation gain (loss) 0        
Balance at Jun. 30, 2026 $ 71,500   $ 554,160 $ (82) $ (482,578)
Balance, Shares at Jun. 30, 2026   53,460,432      
XML 13 R6.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities:    
Net loss $ (36,124) $ (38,646)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 2,935 3,176
Depreciation 58 69
Accretion of discounts on marketable securities (767) (1,564)
Non-cash lease income (5) (4)
Gain on termination of lease, net (24) 0
Loss on sales and disposals of fixed assets, net 25 38
Other, net 1 (16)
Change in operating assets and liabilities:    
Prepaid expenses and other assets 306 3,167
Operating lease right-of-use assets and liabilities 0 0
Accounts payable (1,135) (3,981)
Accrued expenses 474 1,193
Net cash used in operating activities (34,256) (36,568)
Cash flows from investing activities:    
Purchases of property and equipment 0 (15)
Proceeds from sale of property and equipment 0 30
Purchases of marketable securities (37,404) (46,689)
Maturities of marketable securities 46,001 86,374
Net cash provided by investing activities 8,597 39,700
Cash flows from financing activities:    
Proceeds from the exercise of stock options and common stock issued under the 2020 Plan 143 113
Net cash provided by financing activities 143 113
Impact of exchange rates on cash and cash equivalents 2 6
Net (decrease) increase in cash and cash equivalents (25,514) 3,251
Cash and cash equivalents    
Cash and cash equivalents - beginning of period 37,983 40,876
Cash and cash equivalents - end of period $ 12,469 $ 44,127
XML 14 R7.htm IDEA: XBRL DOCUMENT v3.26.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Pay vs Performance Disclosure            
Net Income (Loss) $ (18,086) $ (18,038) $ (21,210) $ (17,436) $ (36,124) $ (38,646)
XML 15 R8.htm IDEA: XBRL DOCUMENT v3.26.1
Insider Trading Arrangements
3 Months Ended
Jun. 30, 2026
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 16 R9.htm IDEA: XBRL DOCUMENT v3.26.1
Formation and Business of the Company
6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Formation and Business of the Company

1. Formation and Business of the Company

Organization and Liquidity

PMV Pharmaceuticals, Inc. (the “Company”) was incorporated in the state of Delaware in March 2013. Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities and raising capital. The Company is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The Company’s headquarters are located at 400 Alexander Park Drive, Suite 301, Princeton, New Jersey.

The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

The Company has incurred net losses and negative cash flows from operations since its inception. During the three and six months ended June 30, 2026, the Company incurred a net loss of $18,086 and $36,124, respectively. For the six months ended June 30, 2026, the Company used $34,256 of cash for operations. At June 30, 2026, the Company had an accumulated deficit of $482,578. Cash, cash equivalents, and marketable securities were $79,431 as of June 30, 2026. Management expects to incur substantial additional operating losses for the next several years and may need to obtain additional debt or equity financings in order to complete development of its products, obtain regulatory approvals, launch and commercialize its products.

Liquidity and Going Concern

Management has determined that the Company’s current available cash, cash equivalents and marketable securities may not be sufficient to fund its planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to the Company’s ability to continue as a going concern.

The Company’s ability to continue as a going concern will depend on, among other things, its ability to obtain additional funding and appropriately manage the amount of cash used to fund its operations. The Company plans to address this condition through public or private equity, convertible or debt financing or capital obtained in connection with strategic collaborations or licensing or other sources. There are inherent uncertainties as the outcome of these potential transactions are outside management’s control, and therefore there are no assurances that any of these potential transactions will occur. In addition, there can be no assurances that these transactions will sufficiently improve the Company’s liquidity or that the Company will otherwise realize the anticipated benefits. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, suspend or curtail planned programs, or pursue strategic alternatives. Any of these actions could materially harm the Company’s business, results of operations and future prospects.

The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the unaudited condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

XML 17 R10.htm IDEA: XBRL DOCUMENT v3.26.1
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2025, included in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 6, 2026. Since the date of those consolidated financial statements, there have been no changes to its significant accounting policies.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the interim period reporting requirements of Form 10-Q and Article 10 of Regulation S-X. The condensed consolidated balance sheet as of June 30, 2026, the condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of stockholders’ equity and condensed consolidated statements of cash flows for the three and six months ended June 30, 2026 and 2025 are unaudited, but, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for any interim period are not necessarily indicative of results for the year ending December 31, 2026, or for any other subsequent interim period. The condensed consolidated balance sheet as of December 31, 2025, has been derived from the Company’s audited consolidated financial statements.

The accompanying condensed consolidated financial statements include the Company’s accounts and the accounts of its wholly owned subsidiary, PMV Pharma Australia Pvt Ltd. All significant intercompany transactions and balances have been eliminated upon consolidation. These condensed consolidated financial statements are presented in United States (“U.S.”) Dollars, which is also the functional currency of the Company.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development costs, accrued research and development costs and related prepaid expenses, and stock-based compensation. Actual results could differ materially from those estimates.

Fair Value of Financial Instruments

The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:

•
Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
•
Level 2 - Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.
•
Level 3 - Inputs are unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions that are unobservable.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

Cash, Cash Equivalents, and Marketable Securities

Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents.

The Company’s marketable debt securities have been classified and accounted for as available-for-sale. The Company classifies its marketable debt securities as either short-term or long-term based on each instrument’s underlying contractual

maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. The Company’s marketable debt securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in stockholders’ equity. Premiums and discounts on marketable debt securities are amortized into earnings over the life of the security and recorded on the interest income, net line of the income statement. For the six months ended June 30, 2026 and 2025, the Company recorded $767 and $1,564 of accretion, respectively.

Property and Equipment

Property and equipment are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight‑line method over the estimated useful lives of the assets, generally five years, except for leasehold improvements, which are amortized over the shorter of the useful life of the asset or the remaining term of the lease. Upon retirement or sale of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Repairs and maintenance costs are charged to operations as incurred.

 

Comprehensive Loss and Accumulated Other Comprehensive Income (Loss)

Other comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation gains and losses.

Leases

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset’s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (“ROU”) assets and operating lease liabilities at the lease commencement date, and thereafter if modified. The lease term includes any renewal options that the Company is reasonably certain to exercise. The Company’s policy is to not record leases with a lease term of 12 months or less on its balance sheets. The Company's only existing lease recorded on the balance sheet is for office space.

The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.

Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations.

Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company’s share of the lessor’s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Variable payments have been excluded from the lease liability and associated right-of-use asset. Neither of the Company’s leases contain residual value guarantees.

The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash, cash equivalents, and marketable securities. Cash and cash equivalents were held at primarily two financial institutions. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash

and cash equivalents. The Company’s marketable securities are carried at fair value and include any unrealized gains and losses. Any investments with unrealized losses are considered to be temporarily impaired.

The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, cost of development, uncertainty of market acceptance of the product, competition from substitute products and larger companies, protection of proprietary technology, any future strategic relationships and dependence on key individuals.

Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company’s product candidates will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or it is unable to maintain clearance, it could have a materially adverse impact on the Company.

Recently Adopted Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amended guidance enhances income tax disclosures primarily related to the effective tax rate reconciliation and income taxes paid information. This guidance requires disclosure of specific categories in the effective tax rate reconciliation and additional information on reconciling items meeting a quantitative threshold. In addition, the amended guidance requires disaggregating income taxes paid (net of refunds received) by federal, state, and foreign taxes. It also requires disaggregating individual jurisdictions in which income taxes paid (net of refunds received) are equal to or greater than 5 percent of total income taxes paid (net of refunds received). The amended guidance is effective for annual periods beginning after December 15, 2024. The Company adopted this guidance prospectively for the annual period ending December 31, 2025. For additional information, see “Note 9 — Income Taxes.”

Recent Accounting Pronouncements Not Yet Adopted

In November 2024, the FASB issued ASU 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses”. This amended guidance requires disaggregation of specific expense categories in the notes to the financial statements and a qualitative description of the remaining expense amounts not separately disaggregated. This standard becomes effective for reporting companies with annual reporting periods beginning after December 15, 2026, and requires prospective application with an option to apply it retrospectively. The Company anticipates adopting this standard in its Annual Report on Form 10-K for the year ending December 31, 2027. The Company is currently evaluating the impact that the adoption of this standard will have on its condensed consolidated financial statements.

In September 2025, the FASB issued ASU 2025-07 (“ASU 2025-07”), Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606). The guidance refines the scope of Topic 815 to clarify which contracts are subject to derivative accounting. The guidance also provides clarification under Topic 606 for share-based payments from a customer in a revenue contract. The amendments in ASU 2025-07 are effective for fiscal years beginning after December 15, 2026, and interim reporting periods, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its condensed consolidated financial statements.

XML 18 R11.htm IDEA: XBRL DOCUMENT v3.26.1
Fair Value Measurements
6 Months Ended
Jun. 30, 2026
Fair Value Disclosures [Abstract]  
Fair Value Measurements

3. Fair Value Measurements

The Company’s financial instruments consist of money market funds, U.S. government debt securities and corporate debt securities. Cash and cash equivalents includes money market funds, corporate securities, and government securities, which are measured at fair value on a recurring basis using quoted prices and are classified as Level 1. Marketable securities are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified

as Level 2 inputs, except for investments in U.S. treasury securities and certificates of deposit which are classified as Level 1. There were no Level 3 assets or liabilities at June 30, 2026.

The following tables show the Company’s cash equivalents and available-for-sale securities’ carrying amounts and fair values as of June 30, 2026, and December 31, 2025:

 

 

 

As of June 30, 2026

 

 

 

Carrying
Amount

 

 

Gross Unrealized Gains

 

 

Gross Unrealized Losses

 

 

Fair
Value

 

 

Quoted
priced in
active
markets
(Level 1)

 

 

Significant
other
observable
inputs
(Level 2)

 

 

Significant
unobservable
inputs
(Level 3)

 

Financial assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

12,436

 

 

$

—

 

 

$

—

 

 

$

12,436

 

 

$

12,436

 

 

$

—

 

 

$

—

 

Corporate securities

 

 

44,867

 

 

 

—

 

 

 

(65

)

 

 

44,802

 

 

 

—

 

 

 

44,802

 

 

 

—

 

Government securities

 

 

22,186

 

 

 

1

 

 

 

(27

)

 

 

22,160

 

 

 

22,160

 

 

 

—

 

 

 

—

 

Total financial assets

 

$

79,489

 

 

$

1

 

 

$

(92

)

 

$

79,398

 

 

$

34,596

 

 

$

44,802

 

 

$

—

 

 

 

 

 

As of December 31, 2025

 

 

 

Carrying
Amount

 

 

Gross Unrealized Gains

 

 

Gross Unrealized Losses

 

 

Fair
Value

 

 

Quoted
Priced in
Active
Markets
(Level 1)

 

 

Significant
Other
Observable
Inputs
(Level 2)

 

 

Significant
Unobservable
Inputs
(Level 3)

 

Financial assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

29,909

 

 

$

—

 

 

$

—

 

 

$

29,909

 

 

$

29,909

 

 

$

—

 

 

$

—

 

Corporate securities

 

 

30,636

 

 

 

12

 

 

 

(4

)

 

 

30,644

 

 

 

—

 

 

 

30,644

 

 

 

—

 

Government securities

 

 

52,229

 

 

 

68

 

 

 

—

 

 

 

52,297

 

 

 

52,297

 

 

 

—

 

 

 

—

 

Total financial assets

 

$

112,774

 

 

$

80

 

 

$

(4

)

 

$

112,850

 

 

$

82,206

 

 

$

30,644

 

 

$

—

 

 

 

Cash Equivalents — As of June 30, 2026, the Company had aggregate cash and cash equivalents of $12,469, including cash equivalents of $12,436, consisting of money market funds and government securities. As of December 31, 2025, the Company had aggregate cash and cash equivalents of $37,983, including cash equivalents of $29,909, consisting of money market funds, and $7,981 in corporate securities.

Marketable Securities — Marketable securities of $66,962 as of June 30, 2026, consisted of corporate debt securities of $44,802 and government debt securities of $22,160. All marketable securities were classified as current, and the Company held no noncurrent marketable securities, as of June 30, 2026. Marketable securities of $74,960 as of December 31, 2025, consisted of corporate debt securities of $22,663 and government debt securities of $52,298. There were $74,960 of current marketable
securities and
no noncurrent marketable securities as of December 31, 2025.

As of June 30, 2026, and December 31, 2025, aggregated gross unrealized losses of available-for-sale investments were not material, and accordingly, no allowance for credit losses was recorded.

XML 19 R12.htm IDEA: XBRL DOCUMENT v3.26.1
Property and Equipment, Net
6 Months Ended
Jun. 30, 2026
Property, Plant, and Equipment [Abstract]  
Property and Equipment, Net

4. Property and Equipment, Net

 

 

 

June 30,
2026

 

 

December 31,
2025

 

Machinery & equipment

 

$

1,428

 

 

$

1,447

 

Computers

 

 

13

 

 

 

13

 

Furniture & fixtures

 

 

23

 

 

 

23

 

Leasehold improvements

 

 

45

 

 

 

81

 

Total property and equipment

 

 

1,509

 

 

 

1,564

 

Less: Accumulated depreciation

 

 

(1,355

)

 

 

(1,327

)

Property and equipment, net

 

$

154

 

 

$

237

 

 

 

 

Depreciation expense for the three months ended June 30, 2026 and 2025 was $24 and $32, respectively. Depreciation expense for the six months ended June 30, 2026 and 2025 was $58 and $69, respectively.

XML 20 R13.htm IDEA: XBRL DOCUMENT v3.26.1
Accrued Expenses
6 Months Ended
Jun. 30, 2026
Payables and Accruals [Abstract]  
Accrued Expenses

5. Accrued Expenses

Accrued expenses consist of the following:

 

 

June 30,
2026

 

 

December 31,
2025

 

Accrued compensation

 

$

3,203

 

 

$

4,532

 

Accrued research and development costs

 

 

4,865

 

 

 

3,130

 

Accrued legal and professional services

 

 

263

 

 

 

195

 

Total

 

$

8,331

 

 

$

7,857

 

XML 21 R14.htm IDEA: XBRL DOCUMENT v3.26.1
Commitments and Contingencies
6 Months Ended
Jun. 30, 2026
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

6. Commitments and Contingencies

Operating Leases

In January 2021, the Company signed a lease for 50,581 square feet of office and laboratory space (the “One Research Way Lease”) at One Research Way in Princeton, New Jersey (the “Premises”). The lease term initially extended through 2032, had a five-year extension option, and replaced the Company’s two prior facilities as the Company’s headquarters in March 2023. The Company estimated that payments under the One Research Way Lease would be $19,889 through May 2032. The Company received a lease incentive of $4,046 from the lessor for a buildout of laboratory, vivarium, and office space. Management estimated the timing and amounts of reimbursements and included them as a reduction of lease payments when initially measuring the lease liability and right-of-use asset upon commencement. Since the inception date of the lease, $4,046 reimbursements were received from the lessor.

In August 2024, the Company entered into a Lease Termination Agreement with BMR-One Research Way LLC (the “Landlord”), in connection with the termination of the One Research Way Lease (the “Termination Agreement”). The Termination Agreement was contingent on the sale of the Premises by the Landlord to a prospective new buyer, which was met on October 1, 2024, and, as a result, there was no modification in August 2024.

Pursuant to the Termination Agreement, the Company surrendered the Premises in October 2024 and paid a total termination fee of approximately $1,420, consisting of (i) a cash payment in the amount of approximately $798 and (ii) a release of a security deposit from the Company’s existing letter of credit in the amount of approximately $622. The transaction was accounted for as an immediate termination of an operating lease before the expiration of the lease term in accordance with ASC 842. The Company derecognized the lease-related asset and liability resulting in a gain of $4,850. Since the termination fee of $1,420 was not already included in the lease payments, the termination fee was recognized as a loss on termination of the lease. Further, the Company abandoned and wrote-off all the related leasehold improvements totaling $9,454 held at the Premises. This net activity totaling $6,024 was recorded as a loss within General and Administrative expense in the Statement of Operations for the year ended December 31, 2024.

In August 2024, the Company signed a sublease for 14,201 square feet of office space at 400 Alexander Park Drive, Suite 301, in Princeton, New Jersey, to be used as its new headquarters (the “400 Alexander Sublease”). The 400 Alexander Sublease commenced on October 1, 2024 and extends until February 28, 2027. Payment under the 400 Alexander Sublease will total $789 through February 2027.

In September 2024, the Company signed a sublease agreement for 3,205 square feet of office and laboratory space at 311 Pennington Rocky Hill Road in Hopewell, New Jersey (the “311 Pennington Sublease”). The Company utilized the premises as laboratory space for research and development activities. The term of the 311 Pennington Sublease extended through 2029 and provided the Company with the option to extend the term for an additional three year period. Payment under the 311 Pennington Sublease totaled $192 through February 2026.

In March 2026, the 311 Pennington Sublease was terminated effective March 4, 2026, upon the termination of the primary lease between the master landlord and the tenant, in accordance with the terms of the sublease agreement. As a result, the Company accounted for the 311 Pennington Sublease termination as an immediate termination of an operating lease before the expiration of the lease term in accordance with ASC 842. Upon termination, the Company derecognized the related operating lease right‑of‑use asset and lease liabilities and recorded a net gain of approximately $24, which was recognized in General and Administrative expense in the accompanying Statement of Operations for the three months ended March 31, 2026.

The components of lease cost for the three and six months ended June 30, 2026 and 2025, were as follows:

 

 

 

Three Months Ended June 30,

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Operating lease cost

 

$

82

 

 

$

118

 

 

 

187

 

 

 

235

 

Variable lease cost

 

 

1

 

 

 

18

 

 

 

21

 

 

 

34

 

Short-term lease cost

 

 

75

 

 

 

—

 

 

 

100

 

 

 

—

 

Total lease cost

 

$

158

 

 

$

136

 

 

$

308

 

 

$

269

 

 

 

Amounts reported in the balance sheet for leases where the Company is the lessee as of June 30, 2026, and December 31, 2025, are as follows:

 

Operating Leases

 

June 30,
2026

 

 

December 31,
2025

 

Right-of-use assets, operating leases

 

$

209

 

 

$

801

 

 

 

 

 

 

 

Operating lease liabilities, current

 

$

217

 

 

$

403

 

Operating lease liabilities, non-current

 

 

-

 

 

 

435

 

Total operating lease liabilities

 

$

217

 

 

$

838

 

 

 

 

 

 

 

Weighted-average remaining lease term (years)

 

 

0.67

 

 

 

2.76

 

Weighted-average discount rate

 

 

13.70

%

 

 

13.70

%

 

 

Other information related to leases for the six months ended June 30, 2026 and 2025, respectively, are as follows:

 

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

Net cash paid for amounts included in the measurement of lease liabilities

 

$

193

 

 

$

240

 

Leased assets (derecognized) in exchange for new or modified operating lease liabilities

 

 

(432

)

 

 

(170

)

 

 

Future minimum lease payments, net of reimbursements, remaining as of June 30, 2026, under operating leases by fiscal year were as follows:

 

Fiscal year

 

 

 

2026

 

$

169

 

2027

 

 

56

 

2028

 

 

 

2029

 

 

 

Thereafter

 

 

 

Total minimum lease payments

 

$

225

 

Less: Amounts representing imputed interest

 

 

(8

)

Present value of lease liabilities

 

$

217

 

 

 

Rent expense recorded during the three months ended June 30, 2026 and 2025 was $157 and $118, respectively. Rent expense recorded during the six months ended June 30, 2026 and 2025 was $287 and $235, respectively.

Contingencies

From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when future expenditures are probable and such expenditures can be reasonably estimated.

XML 22 R15.htm IDEA: XBRL DOCUMENT v3.26.1
Stockholders' Equity
6 Months Ended
Jun. 30, 2026
Equity [Abstract]  
Stockholders' Equity

7. Stockholders’ Equity

The Company is authorized to issue up to 1,000,000,000 shares of common stock with a par value of $0.00001 per share and 5,000,000 shares of preferred stock with a par value of $0.00001 per share. At June 30, 2026 and December 31, 2025, there were 53,460,432 and 53,331,766 shares of common stock issued and outstanding, respectively.

Common stockholders are entitled to receive dividends if and when declared by the board of directors subject to the rights of any preferred stockholders. As of June 30, 2026, no dividends on common stock had been declared by the Company.

ATM Program

On October 4, 2021, the Company entered into an at-the-market offering program (the “ATM Program”). Pursuant to the ATM Program, the Company may offer and sell shares of its common stock having aggregate gross sales proceeds of up to $150.0 million from time to time. During the three and six months ended June 30, 2026, the Company did not sell any shares of its common stock under the ATM Program. As of June 30, 2026, the Company has approximately $113.8 million remaining in gross proceeds available for future issuances of common stock under the ATM Program.

XML 23 R16.htm IDEA: XBRL DOCUMENT v3.26.1
Stock Plan
6 Months Ended
Jun. 30, 2026
Share-Based Payment Arrangement [Abstract]  
Stock Plan

8. Stock Plan

2020 Equity Incentive Plan

The 2020 Equity Incentive Plan (the “2020 Plan”) was approved by the Company’s board of directors on September 24, 2020. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The number of shares of common stock initially reserved for issuance under the 2020 Plan was 4,406,374, which shall be increased, upon approval by the Company’s board of directors, on January 1, 2021 and each January 1 thereafter, in an amount equal to the least of (i) 4,406,374 shares of common stock, (ii) five percent (5%) of the outstanding common stock on the immediately preceding December 31, or (iii) such number of common stock determined by the board of directors no later than the immediately preceding December 31. For 2026, the compensation committee of the Company’s board of directors, as the 2020 Plan administrator, exercised its discretion under clause (ii) to increase the number of shares of common stock reserved for issuance under the 2020 Plan by 2,666,470 shares, effective as of January 1, 2026. As of June 30, 2026, there were 3,185,748 shares available for issuance under the 2020 Plan.

On January 18, 2024, the Company granted 952,665 RSUs to employees VP-level or higher, pursuant to an employee retention program approved by the compensation committee of the Company’s board of directors. As of June 30, 2025 such RSUs were fully vested and common stock was issued upon settlement of the RSUs.

2020 Employee Stock Purchase Plan

The 2020 Employee Stock Purchase Plan (the “2020 ESPP”) was approved by the Company’s board of directors on September 24, 2020. A total of 400,752 shares of common stock were initially reserved for issuance under this plan, which shall be increased, upon approval by the Company’s board of directors, on January 1, 2021 and each January 1 thereafter, to the lesser of (i) 801,504 shares of common stock, (ii) 1% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (iii) an amount determined by the board of directors or any of its committees no later than the last day of the immediately preceding fiscal year. For 2026, the Company’s board of directors waived the annual increase to the shares reserved under the 2020 ESPP. As of June 30, 2026, 740,081 shares are issued or outstanding, and there were 1,033,530 shares available for issuance, under the 2020 ESPP.

Stock Options

On July 16, 2024, the Company filed with the Securities and Exchange Commission a Tender Offer Statement on Schedule TO defining the terms and conditions of a one-time voluntary stock option exchange to its employees of certain options to purchase up to an aggregate of 2,820,491 shares of the Company’s common stock (the “Option Exchange”). On August 13, 2024, the completion date of the Option Exchange, stock options covering an aggregate of 2,786,691 shares of common stock were tendered by eligible employees, and the Company granted new options at an exercise price of $1.48, the Company’s closing stock price on August 13, 2024, covering an aggregate of 2,786,691 shares of common stock under the 2020 Plan in exchange for the tendered options. The new options are subject to a new three or four-year vesting schedule,

vesting in equal annual installments over the vesting term. Each new option has a maximum term of ten years. The Option Exchange was treated as a modification for accounting purposes. As a result of the Option Exchange, the Company will recognize incremental stock-based compensation expense of $1,370 over the requisite service period of the new stock options, which is three or four years. The Company will recognize the sum of the incremental stock-based compensation expense and the remaining unrecognized compensation expense for the original awards on the modification date, over the requisite service period of the new stock options.

The following table summarizes option activity for the six-month period ended June 30, 2026:

 

 

 

Options Outstanding

 

 

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

 

Weighted

 

 

Average

 

 

Aggregate

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Intrinsic

 

 

 

Number of

 

 

Exercise

 

 

Contractual Life

 

 

Value

 

 

 

Options

 

 

Price

 

 

(in years)

 

 

(in 000s)

 

Balances at December 31, 2025

 

 

11,990,688

 

 

$

2.43

 

 

 

7.74

 

 

$

86

 

Options granted

 

 

3,898,665

 

 

$

1.51

 

 

 

 

 

 

 

Options forfeited / cancelled

 

 

(79,818

)

 

$

1.70

 

 

 

 

 

 

 

Options exercised

 

 

—

 

 

 

—

 

 

 

 

 

 

 

Balances June 30, 2026 (unaudited)

 

 

15,809,535

 

 

$

2.21

 

 

 

7.83

 

 

$

218

 

At June 30, 2026

 

 

 

 

 

 

 

 

 

 

 

 

Vested and expected to vest

 

 

15,809,535

 

 

$

2.21

 

 

 

7.83

 

 

$

218

 

Exercisable

 

 

7,191,393

 

 

$

3.06

 

 

 

6.58

 

 

$

110

 

 

 

At June 30, 2026, the total compensation cost related to nonvested awards not yet recognized was $12,278. The weighted-average period over which the nonvested awards is expected to be recognized was 2.7 years.

The Company estimated the fair value of the options using the Black-Scholes options valuation model. The fair value of the options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value was estimated using the following assumptions:

 

 

 

For the Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

Risk-free interest rate

 

 

3.82% - 4.27%

 

 

 

3.89% - 4.48%

 

Expected life (in years)

 

 

5.50 - 6.25

 

 

 

5.50 - 6.25

 

Dividend yield

 

 

0%

 

 

 

0%

 

Expected volatility

 

 

77.29% - 77.77%

 

 

 

78.67% - 80.22%

 

 

 

The weighted average assumptions used to estimate the fair value of stock purchase rights under the ESPP are as follows:

 

 

 

For the Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

Risk-free interest rate

 

 

3.75%

 

 

 

4.33%

 

Expected life (in years)

 

 

0.50

 

 

 

0.50

 

Dividend yield

 

 

0%

 

 

 

0%

 

Expected volatility

 

 

77.77%

 

 

 

78.67%

 

 

 

Risk Free Interest Rate: The risk-free rate is based on the U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected term of the option.

Expected Term: The Company uses the simplified method to calculate expected term described in the SEC’s Staff Accounting Bulletin No. 107, which takes into account vesting term and expiration date of the options.

Dividend Yield: The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model.

Volatility: Volatility is based on the historical volatility of the Company’s publicly traded shares for the expected term.

Restricted Stock Units

For the quarter ending June 30, 2026, no RSU awards were granted, vested, or unvested. As of June 30, 2026 there was no unrecognized compensation cost related to RSUs that are expected to vest.

 

 

 

Stock-based compensation expense recorded under ASC 718 related to stock options granted and common stock issued under the 2020 ESPP were allocated to research and development and general and administrative expense as follows:

 

 

 

For the Three Months Ended June 30,

 

 

For the Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Research and development

 

$

697

 

 

$

741

 

 

$

1,335

 

 

$

1,377

 

General and administrative

 

 

846

 

 

 

927

 

 

 

1,600

 

 

 

1,799

 

Total stock-based compensation

 

$

1,543

 

 

$

1,668

 

 

$

2,935

 

 

$

3,176

 

 

 

Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:

 

 

 

For the Three Months Ended June 30,

 

 

For the Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Stock options

 

$

1,510

 

 

$

1,341

 

 

$

2,870

 

 

$

2,516

 

Restricted stock units

 

 

—

 

 

 

281

 

 

 

—

 

 

 

559

 

Employee stock purchase plan

 

 

33

 

 

 

46

 

 

 

65

 

 

 

101

 

Total stock-based compensation

 

$

1,543

 

 

$

1,668

 

 

$

2,935

 

 

$

3,176

 

XML 24 R17.htm IDEA: XBRL DOCUMENT v3.26.1
Income Taxes
6 Months Ended
Jun. 30, 2026
Income Tax Disclosure [Abstract]  
Income Taxes

9. Income Taxes

The Company’s effective tax rates were 0% and 0% for the three months ended June 30, 2026 and 2025, respectively.

During the three and six months ended June 30, 2026 and 2025, the Company recorded a full valuation allowance on federal and state net deferred tax assets since management does not forecast the Company to be in a taxable position in the near future.

The State of New Jersey’s Technology Business Tax Certificate Program allows certain high technology and biotechnology companies to sell unused net-operating loss (“NOL”) carryforwards and R&D tax credits to other New Jersey-based corporate taxpayers. For the six months ended June 30, 2025, we received a benefit for income taxes of $2,196. As of June 30, 2025, the Company received $18,372 of cash for the NOL and R&D tax credit sales related to the tax years ended December 31, 2015 to 2023. For the six months ended June 30, 2026, the Company did not receive any benefit for income taxes.

XML 25 R18.htm IDEA: XBRL DOCUMENT v3.26.1
Net Loss per Share
6 Months Ended
Jun. 30, 2026
Earnings Per Share [Abstract]  
Net Loss per Share

10. Net Loss per Share

The Company excluded all outstanding stock options and RSUs at each period end from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect. The following common stock equivalents were excluded from the calculation of diluted net loss per share:

 

 

 

As of June 30,

 

 

 

2026

 

 

2025

 

Options to purchase common stock

 

 

15,809,535

 

 

 

12,211,331

 

Expected shares to be purchased under 2020 ESPP

 

 

6,845

 

 

 

6,845

 

Total

 

 

15,816,380

 

 

 

12,218,176

 

 

XML 26 R19.htm IDEA: XBRL DOCUMENT v3.26.1
Related Parties
6 Months Ended
Jun. 30, 2026
Related Party Transactions [Abstract]  
Related Parties

11. Related Parties

The Company has consulting agreements with two members of its board of directors. Total consulting fees paid during the three months ended June 30, 2026 and 2025 were $30 and $50, respectively. Total consulting fees paid during the six months ended June 30, 2026 and 2025 were $60 and $100, respectively. There were no amounts owed under the consulting agreements as of June 30, 2026.

XML 27 R20.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information
6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information

12. Segment Information

The Company has viewed its operations and manages its business as one operating and reporting segment. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the Company’s CODM to make decisions with respect to resource allocation and assessment of performance. The Company’s CODM is its Chief Executive Officer (the “CEO”), who reviews and evaluates consolidated net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods. The determination of a single segment is consistent with the financial information regularly reviewed by the CEO.

The CEO regularly reviews the condensed consolidated statement of operations and a disaggregation of operating expenses, of which the significant expenses are related to research and development. The following table represents the significant segment expenses regularly provided to the CEO:

 

 

 

For the Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

Research and Development

 

 

 

 

 

 

Research

 

$

1,487

 

 

$

2,571

 

Development

 

 

19,350

 

 

 

24,875

 

Personnel related

 

 

7,834

 

 

 

7,018

 

Stock-based compensation

 

 

1,335

 

 

 

1,377

 

Total research and development

 

 

30,006

 

 

$

35,841

 

General and administration

 

 

 

 

 

 

Personnel related

 

$

2,992

 

 

$

2,896

 

Stock-based compensation

 

 

1,600

 

 

 

1,799

 

External

 

 

3,302

 

 

 

3,905

 

Total general and administrative

 

 

7,894

 

 

 

8,600

 

Loss from Operations

 

$

37,900

 

 

$

44,441

 

XML 28 R21.htm IDEA: XBRL DOCUMENT v3.26.1
Subsequent Event
6 Months Ended
Jun. 30, 2026
Subsequent Events [Abstract]  
Subsequent Event

13. Subsequent Event

The Company has evaluated subsequent events through August 14, 2026, the date these financial statements were issued. The Company determined that there were no subsequent events that required adjustment to or disclosure in the financial statements.

XML 29 R22.htm IDEA: XBRL DOCUMENT v3.26.1
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the interim period reporting requirements of Form 10-Q and Article 10 of Regulation S-X. The condensed consolidated balance sheet as of June 30, 2026, the condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of stockholders’ equity and condensed consolidated statements of cash flows for the three and six months ended June 30, 2026 and 2025 are unaudited, but, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for any interim period are not necessarily indicative of results for the year ending December 31, 2026, or for any other subsequent interim period. The condensed consolidated balance sheet as of December 31, 2025, has been derived from the Company’s audited consolidated financial statements.

The accompanying condensed consolidated financial statements include the Company’s accounts and the accounts of its wholly owned subsidiary, PMV Pharma Australia Pvt Ltd. All significant intercompany transactions and balances have been eliminated upon consolidation. These condensed consolidated financial statements are presented in United States (“U.S.”) Dollars, which is also the functional currency of the Company.

Use of Estimates

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development costs, accrued research and development costs and related prepaid expenses, and stock-based compensation. Actual results could differ materially from those estimates.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:

•
Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
•
Level 2 - Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.
•
Level 3 - Inputs are unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions that are unobservable.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

Cash, Cash Equivalents, and Marketable Securities

Cash, Cash Equivalents, and Marketable Securities

Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents.

The Company’s marketable debt securities have been classified and accounted for as available-for-sale. The Company classifies its marketable debt securities as either short-term or long-term based on each instrument’s underlying contractual

maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. The Company’s marketable debt securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in stockholders’ equity. Premiums and discounts on marketable debt securities are amortized into earnings over the life of the security and recorded on the interest income, net line of the income statement. For the six months ended June 30, 2026 and 2025, the Company recorded $767 and $1,564 of accretion, respectively.

Property and Equipment

Property and Equipment

Property and equipment are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight‑line method over the estimated useful lives of the assets, generally five years, except for leasehold improvements, which are amortized over the shorter of the useful life of the asset or the remaining term of the lease. Upon retirement or sale of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Repairs and maintenance costs are charged to operations as incurred.

Comprehensive Loss and Accumulated Other Comprehensive Income (Loss)

Comprehensive Loss and Accumulated Other Comprehensive Income (Loss)

Other comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation gains and losses.

Leases

Leases

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset’s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (“ROU”) assets and operating lease liabilities at the lease commencement date, and thereafter if modified. The lease term includes any renewal options that the Company is reasonably certain to exercise. The Company’s policy is to not record leases with a lease term of 12 months or less on its balance sheets. The Company's only existing lease recorded on the balance sheet is for office space.

The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.

Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations.

Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company’s share of the lessor’s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Variable payments have been excluded from the lease liability and associated right-of-use asset. Neither of the Company’s leases contain residual value guarantees.

The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.

Concentration of Credit Risk and Other Risks and Uncertainties

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash, cash equivalents, and marketable securities. Cash and cash equivalents were held at primarily two financial institutions. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash

and cash equivalents. The Company’s marketable securities are carried at fair value and include any unrealized gains and losses. Any investments with unrealized losses are considered to be temporarily impaired.

The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, cost of development, uncertainty of market acceptance of the product, competition from substitute products and larger companies, protection of proprietary technology, any future strategic relationships and dependence on key individuals.

Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company’s product candidates will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or it is unable to maintain clearance, it could have a materially adverse impact on the Company.

Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted

Recently Adopted Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amended guidance enhances income tax disclosures primarily related to the effective tax rate reconciliation and income taxes paid information. This guidance requires disclosure of specific categories in the effective tax rate reconciliation and additional information on reconciling items meeting a quantitative threshold. In addition, the amended guidance requires disaggregating income taxes paid (net of refunds received) by federal, state, and foreign taxes. It also requires disaggregating individual jurisdictions in which income taxes paid (net of refunds received) are equal to or greater than 5 percent of total income taxes paid (net of refunds received). The amended guidance is effective for annual periods beginning after December 15, 2024. The Company adopted this guidance prospectively for the annual period ending December 31, 2025. For additional information, see “Note 9 — Income Taxes.”

Recent Accounting Pronouncements Not Yet Adopted

In November 2024, the FASB issued ASU 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses”. This amended guidance requires disaggregation of specific expense categories in the notes to the financial statements and a qualitative description of the remaining expense amounts not separately disaggregated. This standard becomes effective for reporting companies with annual reporting periods beginning after December 15, 2026, and requires prospective application with an option to apply it retrospectively. The Company anticipates adopting this standard in its Annual Report on Form 10-K for the year ending December 31, 2027. The Company is currently evaluating the impact that the adoption of this standard will have on its condensed consolidated financial statements.

In September 2025, the FASB issued ASU 2025-07 (“ASU 2025-07”), Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606). The guidance refines the scope of Topic 815 to clarify which contracts are subject to derivative accounting. The guidance also provides clarification under Topic 606 for share-based payments from a customer in a revenue contract. The amendments in ASU 2025-07 are effective for fiscal years beginning after December 15, 2026, and interim reporting periods, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its condensed consolidated financial statements.

XML 30 R23.htm IDEA: XBRL DOCUMENT v3.26.1
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2026
Fair Value Disclosures [Abstract]  
Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values

The following tables show the Company’s cash equivalents and available-for-sale securities’ carrying amounts and fair values as of June 30, 2026, and December 31, 2025:

 

 

 

As of June 30, 2026

 

 

 

Carrying
Amount

 

 

Gross Unrealized Gains

 

 

Gross Unrealized Losses

 

 

Fair
Value

 

 

Quoted
priced in
active
markets
(Level 1)

 

 

Significant
other
observable
inputs
(Level 2)

 

 

Significant
unobservable
inputs
(Level 3)

 

Financial assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

12,436

 

 

$

—

 

 

$

—

 

 

$

12,436

 

 

$

12,436

 

 

$

—

 

 

$

—

 

Corporate securities

 

 

44,867

 

 

 

—

 

 

 

(65

)

 

 

44,802

 

 

 

—

 

 

 

44,802

 

 

 

—

 

Government securities

 

 

22,186

 

 

 

1

 

 

 

(27

)

 

 

22,160

 

 

 

22,160

 

 

 

—

 

 

 

—

 

Total financial assets

 

$

79,489

 

 

$

1

 

 

$

(92

)

 

$

79,398

 

 

$

34,596

 

 

$

44,802

 

 

$

—

 

 

 

 

 

As of December 31, 2025

 

 

 

Carrying
Amount

 

 

Gross Unrealized Gains

 

 

Gross Unrealized Losses

 

 

Fair
Value

 

 

Quoted
Priced in
Active
Markets
(Level 1)

 

 

Significant
Other
Observable
Inputs
(Level 2)

 

 

Significant
Unobservable
Inputs
(Level 3)

 

Financial assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

29,909

 

 

$

—

 

 

$

—

 

 

$

29,909

 

 

$

29,909

 

 

$

—

 

 

$

—

 

Corporate securities

 

 

30,636

 

 

 

12

 

 

 

(4

)

 

 

30,644

 

 

 

—

 

 

 

30,644

 

 

 

—

 

Government securities

 

 

52,229

 

 

 

68

 

 

 

—

 

 

 

52,297

 

 

 

52,297

 

 

 

—

 

 

 

—

 

Total financial assets

 

$

112,774

 

 

$

80

 

 

$

(4

)

 

$

112,850

 

 

$

82,206

 

 

$

30,644

 

 

$

—

 

XML 31 R24.htm IDEA: XBRL DOCUMENT v3.26.1
Property and Equipment, Net (Tables)
6 Months Ended
Jun. 30, 2026
Property, Plant, and Equipment [Abstract]  
Summary of Property and Equipment, Net

 

 

June 30,
2026

 

 

December 31,
2025

 

Machinery & equipment

 

$

1,428

 

 

$

1,447

 

Computers

 

 

13

 

 

 

13

 

Furniture & fixtures

 

 

23

 

 

 

23

 

Leasehold improvements

 

 

45

 

 

 

81

 

Total property and equipment

 

 

1,509

 

 

 

1,564

 

Less: Accumulated depreciation

 

 

(1,355

)

 

 

(1,327

)

Property and equipment, net

 

$

154

 

 

$

237

 

XML 32 R25.htm IDEA: XBRL DOCUMENT v3.26.1
Accrued Expenses (Tables)
6 Months Ended
Jun. 30, 2026
Payables and Accruals [Abstract]  
Summary of Accrued Expenses

Accrued expenses consist of the following:

 

 

June 30,
2026

 

 

December 31,
2025

 

Accrued compensation

 

$

3,203

 

 

$

4,532

 

Accrued research and development costs

 

 

4,865

 

 

 

3,130

 

Accrued legal and professional services

 

 

263

 

 

 

195

 

Total

 

$

8,331

 

 

$

7,857

 

XML 33 R26.htm IDEA: XBRL DOCUMENT v3.26.1
Commitments and Contingencies (Tables)
6 Months Ended
Jun. 30, 2026
Commitments and Contingencies Disclosure [Abstract]  
Summary of Components of Lease Cost

The components of lease cost for the three and six months ended June 30, 2026 and 2025, were as follows:

 

 

 

Three Months Ended June 30,

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Operating lease cost

 

$

82

 

 

$

118

 

 

 

187

 

 

 

235

 

Variable lease cost

 

 

1

 

 

 

18

 

 

 

21

 

 

 

34

 

Short-term lease cost

 

 

75

 

 

 

—

 

 

 

100

 

 

 

—

 

Total lease cost

 

$

158

 

 

$

136

 

 

$

308

 

 

$

269

 

Schedule of Amounts Reported in Consolidated Balance Sheets for Leases

Amounts reported in the balance sheet for leases where the Company is the lessee as of June 30, 2026, and December 31, 2025, are as follows:

 

Operating Leases

 

June 30,
2026

 

 

December 31,
2025

 

Right-of-use assets, operating leases

 

$

209

 

 

$

801

 

 

 

 

 

 

 

Operating lease liabilities, current

 

$

217

 

 

$

403

 

Operating lease liabilities, non-current

 

 

-

 

 

 

435

 

Total operating lease liabilities

 

$

217

 

 

$

838

 

 

 

 

 

 

 

Weighted-average remaining lease term (years)

 

 

0.67

 

 

 

2.76

 

Weighted-average discount rate

 

 

13.70

%

 

 

13.70

%

Summary of Other Information Related to Leases

Other information related to leases for the six months ended June 30, 2026 and 2025, respectively, are as follows:

 

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

Net cash paid for amounts included in the measurement of lease liabilities

 

$

193

 

 

$

240

 

Leased assets (derecognized) in exchange for new or modified operating lease liabilities

 

 

(432

)

 

 

(170

)

Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases

Future minimum lease payments, net of reimbursements, remaining as of June 30, 2026, under operating leases by fiscal year were as follows:

 

Fiscal year

 

 

 

2026

 

$

169

 

2027

 

 

56

 

2028

 

 

 

2029

 

 

 

Thereafter

 

 

 

Total minimum lease payments

 

$

225

 

Less: Amounts representing imputed interest

 

 

(8

)

Present value of lease liabilities

 

$

217

 

XML 34 R27.htm IDEA: XBRL DOCUMENT v3.26.1
Stock Plan (Tables)
6 Months Ended
Jun. 30, 2026
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Schedule of Stock Option Activity

The following table summarizes option activity for the six-month period ended June 30, 2026:

 

 

 

Options Outstanding

 

 

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

 

Weighted

 

 

Average

 

 

Aggregate

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Intrinsic

 

 

 

Number of

 

 

Exercise

 

 

Contractual Life

 

 

Value

 

 

 

Options

 

 

Price

 

 

(in years)

 

 

(in 000s)

 

Balances at December 31, 2025

 

 

11,990,688

 

 

$

2.43

 

 

 

7.74

 

 

$

86

 

Options granted

 

 

3,898,665

 

 

$

1.51

 

 

 

 

 

 

 

Options forfeited / cancelled

 

 

(79,818

)

 

$

1.70

 

 

 

 

 

 

 

Options exercised

 

 

—

 

 

 

—

 

 

 

 

 

 

 

Balances June 30, 2026 (unaudited)

 

 

15,809,535

 

 

$

2.21

 

 

 

7.83

 

 

$

218

 

At June 30, 2026

 

 

 

 

 

 

 

 

 

 

 

 

Vested and expected to vest

 

 

15,809,535

 

 

$

2.21

 

 

 

7.83

 

 

$

218

 

Exercisable

 

 

7,191,393

 

 

$

3.06

 

 

 

6.58

 

 

$

110

 

Schedule of Estimated Fair Value of Stock Options

The Company estimated the fair value of the options using the Black-Scholes options valuation model. The fair value of the options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value was estimated using the following assumptions:

 

 

 

For the Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

Risk-free interest rate

 

 

3.82% - 4.27%

 

 

 

3.89% - 4.48%

 

Expected life (in years)

 

 

5.50 - 6.25

 

 

 

5.50 - 6.25

 

Dividend yield

 

 

0%

 

 

 

0%

 

Expected volatility

 

 

77.29% - 77.77%

 

 

 

78.67% - 80.22%

 

Stock-based Compensation Expense Related to Options Granted and Common Stock Issued under 2020 ESPP Recorded and Allocated

Stock-based compensation expense recorded under ASC 718 related to stock options granted and common stock issued under the 2020 ESPP were allocated to research and development and general and administrative expense as follows:

 

 

 

For the Three Months Ended June 30,

 

 

For the Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Research and development

 

$

697

 

 

$

741

 

 

$

1,335

 

 

$

1,377

 

General and administrative

 

 

846

 

 

 

927

 

 

 

1,600

 

 

 

1,799

 

Total stock-based compensation

 

$

1,543

 

 

$

1,668

 

 

$

2,935

 

 

$

3,176

 

Schedule of Stock-based Compensation Expense by Award Type

Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:

 

 

 

For the Three Months Ended June 30,

 

 

For the Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Stock options

 

$

1,510

 

 

$

1,341

 

 

$

2,870

 

 

$

2,516

 

Restricted stock units

 

 

—

 

 

 

281

 

 

 

—

 

 

 

559

 

Employee stock purchase plan

 

 

33

 

 

 

46

 

 

 

65

 

 

 

101

 

Total stock-based compensation

 

$

1,543

 

 

$

1,668

 

 

$

2,935

 

 

$

3,176

 

ESPP  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Schedule of Estimated Fair Value of Stock Options

The weighted average assumptions used to estimate the fair value of stock purchase rights under the ESPP are as follows:

 

 

 

For the Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

Risk-free interest rate

 

 

3.75%

 

 

 

4.33%

 

Expected life (in years)

 

 

0.50

 

 

 

0.50

 

Dividend yield

 

 

0%

 

 

 

0%

 

Expected volatility

 

 

77.77%

 

 

 

78.67%

 

XML 35 R28.htm IDEA: XBRL DOCUMENT v3.26.1
Net Loss per Share (Tables)
6 Months Ended
Jun. 30, 2026
Earnings Per Share [Abstract]  
Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share The following common stock equivalents were excluded from the calculation of diluted net loss per share:

 

 

 

As of June 30,

 

 

 

2026

 

 

2025

 

Options to purchase common stock

 

 

15,809,535

 

 

 

12,211,331

 

Expected shares to be purchased under 2020 ESPP

 

 

6,845

 

 

 

6,845

 

Total

 

 

15,816,380

 

 

 

12,218,176

 

 

XML 36 R29.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information (Tables)
6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Summary of Significant Segment Expenses Regularly Provided to the CEO The following table represents the significant segment expenses regularly provided to the CEO:

 

 

 

For the Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

Research and Development

 

 

 

 

 

 

Research

 

$

1,487

 

 

$

2,571

 

Development

 

 

19,350

 

 

 

24,875

 

Personnel related

 

 

7,834

 

 

 

7,018

 

Stock-based compensation

 

 

1,335

 

 

 

1,377

 

Total research and development

 

 

30,006

 

 

$

35,841

 

General and administration

 

 

 

 

 

 

Personnel related

 

$

2,992

 

 

$

2,896

 

Stock-based compensation

 

 

1,600

 

 

 

1,799

 

External

 

 

3,302

 

 

 

3,905

 

Total general and administrative

 

 

7,894

 

 

 

8,600

 

Loss from Operations

 

$

37,900

 

 

$

44,441

 

XML 37 R30.htm IDEA: XBRL DOCUMENT v3.26.1
Formation and Business of the Company - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]              
Net loss $ 18,086 $ 18,038 $ 21,210 $ 17,436 $ 36,124 $ 38,646  
Cash used in operating activities         34,256 $ 36,568  
Accumulated deficit 482,578       482,578   $ 446,454
Cash, cash equivalents, and marketable securities $ 79,431       $ 79,431    
XML 38 R31.htm IDEA: XBRL DOCUMENT v3.26.1
Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Summary Of Significant Accounting Policies [Line Items]      
Accretion of available-for-sale debt securities $ 767 $ 1,564  
Income tax paid net refund received     5.00%
Property and equipment, Estimated useful lives 5 years    
ASU 2023-09      
Summary Of Significant Accounting Policies [Line Items]      
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]     true
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]     true
XML 39 R32.htm IDEA: XBRL DOCUMENT v3.26.1
Fair Value Measurements - Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Carrying Amount $ 79,489 $ 112,774
Gross Unrealized Gains 1 80
Gross Unrealized Losses (92) (4)
Fair Value 79,398 112,850
Quoted Priced in Active Markets (Level 1)    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total financial assets 34,596 82,206
Significant Other Observable Inputs (Level 2)    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total financial assets 44,802 30,644
Money Market Funds    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Carrying Amount 12,436 29,909
Fair Value 12,436 29,909
Money Market Funds | Quoted Priced in Active Markets (Level 1)    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total financial assets 12,436 29,909
Corporate Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Carrying Amount 44,867 30,636
Gross Unrealized Gains 0 12
Gross Unrealized Losses (65) (4)
Fair Value 44,802 30,644
Corporate Securities | Quoted Priced in Active Markets (Level 1)    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total financial assets 0  
Corporate Securities | Significant Other Observable Inputs (Level 2)    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total financial assets 44,802 30,644
Government Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Carrying Amount 22,186 52,229
Gross Unrealized Gains 1 68
Gross Unrealized Losses (27)  
Fair Value 22,160 52,297
Government Securities | Quoted Priced in Active Markets (Level 1)    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total financial assets 22,160 $ 52,297
Government Securities | Significant Other Observable Inputs (Level 2)    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total financial assets $ 0  
XML 40 R33.htm IDEA: XBRL DOCUMENT v3.26.1
Fair Value Measurements - Additional Information (Details) - USD ($)
Jun. 30, 2026
Dec. 31, 2025
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Aggregate cash and cash equivalents $ 12,469,000 $ 37,983,000
Cash equivalent 12,469,000 37,983,000
Marketable Securities 66,962,000 74,960,000
Marketable securities, noncurrent 0 0
Marketable securities, current 66,962,000 74,960,000
Allowance for credit losses 0 0
Corporate Debt Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalent   7,981,000
Marketable Securities 44,802,000 22,663,000
Government Debt Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable Securities 22,160,000 52,298,000
Money Market Funds    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Aggregate cash and cash equivalents $ 12,436,000  
Money Market Funds and Government Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Aggregate cash and cash equivalents   $ 29,909,000
XML 41 R34.htm IDEA: XBRL DOCUMENT v3.26.1
Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Property Plant And Equipment [Line Items]    
Total property and equipment $ 1,509 $ 1,564
Less: Accumulated depreciation (1,355) (1,327)
Property and equipment, net 154 237
Machinery & Equipment    
Property Plant And Equipment [Line Items]    
Total property and equipment 1,428 1,447
Computers    
Property Plant And Equipment [Line Items]    
Total property and equipment 13 13
Furniture & Fixtures    
Property Plant And Equipment [Line Items]    
Total property and equipment 23 23
Leasehold Improvements    
Property Plant And Equipment [Line Items]    
Total property and equipment $ 45 $ 81
XML 42 R35.htm IDEA: XBRL DOCUMENT v3.26.1
Property and Equipment, Net - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Property, Plant, and Equipment [Line Items]        
Depreciation $ 24 $ 32 $ 58 $ 69
XML 43 R36.htm IDEA: XBRL DOCUMENT v3.26.1
Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Payables and Accruals [Abstract]    
Accrued compensation $ 3,203 $ 4,532
Accrued research and development costs 4,865 3,130
Accrued legal and professional services 263 195
Total $ 8,331 $ 7,857
XML 44 R37.htm IDEA: XBRL DOCUMENT v3.26.1
Commitments and Contingencies - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 30, 2024
USD ($)
ft²
Aug. 31, 2024
USD ($)
ft²
Jan. 31, 2021
USD ($)
ft²
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
ft²
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2025
USD ($)
Commitments And Contingencies Disclosure [Line Items]                    
Rent expense       $ 157   $ 118 $ 287 $ 235    
Loss on termination of lease, net             24 $ 0    
Commitments and contingencies (see Note 6)              
Princeton, New Jersey                    
Commitments And Contingencies Disclosure [Line Items]                    
Lease area of square feet | ft²     50,581              
Operating lease, payments     $ 19,889              
Operating leases extended month and year     2032-05              
Tenant improvement allowance     $ 4,046              
Reimbursements received from lessor     $ 4,046              
Princeton, New Jersey | Sublease Agreement                    
Commitments And Contingencies Disclosure [Line Items]                    
Lease area of square feet | ft²   14,201                
Operating lease, payments   $ 789                
Operating leases extended month and year   2027-02                
Lease commencement date   Oct. 01, 2024                
Lease expiring date   Feb. 28, 2027                
Princeton, New Jersey | Lease Termination Agreement | BMR-One Research Way LLC                    
Commitments And Contingencies Disclosure [Line Items]                    
Operating lease, payments   $ 798                
Termination fee   1,420                
Letter of credit   622                
Loss on termination of lease, net   4,850                
Write off of lease hold improvements   $ 9,454                
Princeton, New Jersey | Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense | Lease Termination Agreement | BMR-One Research Way LLC                    
Commitments And Contingencies Disclosure [Line Items]                    
Net gain (loss) from lease termination agreement                 $ (6,024)  
Hopewell, New Jersey                    
Commitments And Contingencies Disclosure [Line Items]                    
Lease area of square feet | ft²         311          
Loss on termination of lease, net         $ 24          
Hopewell, New Jersey | Sublease Agreement                    
Commitments And Contingencies Disclosure [Line Items]                    
Operating lease, description             The lease term initially extended through 2032, had a five-year extension option, and replaced the Company’s two prior facilities as the Company’s headquarters in March 2023. The term of the 311 Pennington Sublease extended through 2029 and provided the Company with the option to extend the term for an additional three year period.    
Lease area of square feet | ft² 3,205                  
Operating leases, extension period 3 years                  
Operating lease, payments $ 192                  
Operating leases extended month and year 2026-02                  
XML 45 R38.htm IDEA: XBRL DOCUMENT v3.26.1
Commitments and Contingencies - Summary of Components of Lease Cost (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Leases [Abstract]        
Operating lease cost $ 82 $ 118 $ 187 $ 235
Variable lease cost 1 18 21 34
Short-term lease cost 75 0 100 0
Total lease cost $ 158 $ 136 $ 308 $ 269
XML 46 R39.htm IDEA: XBRL DOCUMENT v3.26.1
Commitments and Contingencies - Schedule of Amounts Reported in Consolidated Balance Sheets for Leases (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Operating Leases:    
Right-of-use assets, operating leases $ 209 $ 801
Operating lease liabilities, current 217 403
Operating lease liabilities, non-current 0 435
Total operating lease liabilities $ 217 $ 838
Weighted-average remaining lease term (years) 8 months 1 day 2 years 9 months 3 days
Weighted-average discount rate 13.70% 13.70%
XML 47 R40.htm IDEA: XBRL DOCUMENT v3.26.1
Commitments and Contingencies - Summary of Other Information Related to Leases (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Leases [Abstract]    
Net cash paid for amounts included in the measurement of lease liabilities $ 193 $ 240
Leased assets obtained in exchange for new or modified operating lease liabilities $ (432) $ (170)
XML 48 R41.htm IDEA: XBRL DOCUMENT v3.26.1
Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Commitments and Contingencies Disclosure [Abstract]    
2026 $ 169  
2027 56  
Total minimum lease payments 225  
Less: Amounts representing imputed interest (8)  
Present value of lease liabilities $ 217 $ 838
XML 49 R42.htm IDEA: XBRL DOCUMENT v3.26.1
Stockholders' Equity - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Oct. 04, 2021
Jun. 30, 2026
Jun. 30, 2026
Dec. 31, 2025
Subsidiary, Sale of Stock [Line Items]        
Common stock, shares authorized   1,000,000,000 1,000,000,000 1,000,000,000
Common stock, par value   $ 0.00001 $ 0.00001 $ 0.00001
Common stock, shares issued   53,460,432 53,460,432 53,331,766
Common stock, shares outstanding   53,460,432 53,460,432 53,331,766
Preferred stock, shares authorized   5,000,000 5,000,000 5,000,000
Preferred stock, par value   $ 0.00001 $ 0.00001 $ 0.00001
Dividends, common stock declared     $ 0  
ATM Program        
Subsidiary, Sale of Stock [Line Items]        
Gross proceeds available for future issuances of common stock   $ 113,800,000 $ 113,800,000  
Common stock shares sold   0 0  
Maximum | ATM Program        
Subsidiary, Sale of Stock [Line Items]        
Aggregate gross sales proceeds $ 150,000,000      
XML 50 R43.htm IDEA: XBRL DOCUMENT v3.26.1
Stock Plan - Additional Information (Details) - USD ($)
6 Months Ended
Aug. 13, 2024
Jan. 18, 2024
Jun. 30, 2026
Jun. 30, 2025
Jan. 01, 2025
Jul. 16, 2024
Sep. 24, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Granted options at an exercise price     $ 1.51        
Total compensation cost related to nonvested awards not yet recognized     $ 12,278,000        
Unrecognized compensation cost, weighted average period of recognition     2 years 8 months 12 days        
Dividend yield     0.00% 0.00%      
Option Exchange              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Shares available for future stock option and RSU grants 2,786,691         2,820,491  
Granted options at an exercise price $ 1.48            
Total compensation cost related to nonvested awards not yet recognized $ 1,370,000            
Option Exchange | Minimum              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Unrecognized compensation cost, weighted average period of recognition 3 years            
Option Exchange | Maximum              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Unrecognized compensation cost, weighted average period of recognition 4 years            
Restricted stock units              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Restricted stock units granted to employees   952,665          
Unrecognized compensation cost     $ 0        
2020 Plan              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Number of shares reserved for issuance             4,406,374
Number of additional shares reserved for issuance, minimum             4,406,374
Percentage of number of shares of common stock outstanding increase             5.00%
Number of additional shares reserved for issuance, maximum         2,666,470    
Available for Issuance     3,185,748        
2020 Plan | Option Exchange              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Shares available for future stock option and RSU grants 2,786,691            
2020 ESPP              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Number of shares reserved for issuance     1,033,530       400,752
Percentage of number of shares of common stock outstanding increase             1.00%
Number of additional shares reserved for issuance, maximum             801,504
Shares issued     740,081        
XML 51 R44.htm IDEA: XBRL DOCUMENT v3.26.1
Stock Plan - Schedule of Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2026
Dec. 31, 2025
Number of Options    
Options Outstanding, Number of Options 11,990,688  
Options granted, Number of Options 3,898,665  
Options forfeited / cancelled, Number of Options (79,818)  
Options exercised, Number of Options 0  
Options Outstanding, Number of Options 15,809,535 11,990,688
Vested , Number of Options 15,809,535  
Exercisable, Number of Options 7,191,393  
Weighted Average Exercise Price    
Options Outstanding, Weighted Average Exercise Price $ 2.43  
Options granted, Weighted Average Exercise Price 1.51  
Options forfeited / cancelled, Weighted Average Exercise Price 1.7  
Options exercised, Weighted Average Exercise Price 0  
Options Outstanding, Weighted Average Exercise Price 2.21 $ 2.43
Vested , Weighted Average Exercise Price 2.21  
Exercisable, Weighted Average Exercise Price $ 3.06  
Weighted-Average Remaining Contractual Life    
Options Outstanding, Weighted-Average Remaining Contractual Life 7 years 9 months 29 days 7 years 8 months 26 days
Vested , Weighted-Average Remaining Contractual Life 7 years 9 months 29 days  
Exercisable, Weighted-Average Remaining Contractual Life 6 years 6 months 29 days  
Aggregate Intrinsic Value    
Options Outstanding, Aggregate Intrinsic Value $ 218 $ 86
Vested, Aggregate Intrinsic Value 218  
Exercisable, Aggregate Intrinsic Value $ 110